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 Targeted intracellular delivery is a goal of many novel drug delivery systems to 
treat site-specific diseases, such as cancerous tumors and atherosclerotic lesions, thereby 
increasing the effectiveness of drugs and reducing the side effects associated with current 
drug administration.  The development of ultrasound-enhanced delivery is aimed at 
providing a targeted means to intracellularly deliver drugs and genes by utilizing 
ultrasound’s unique ability to non-invasively focus energy into the body and generate 
cavitation, which has been found to cause transient poration of cells.  Previous research 
of ultrasound-enhanced delivery has concentrated on delivery into in vitro cells in 
suspension and, most recently, in tissues of in vivo animal models in order to understand 
the cavitation-based mechanism, to control the bioeffects, to optimize intracellular 
uptake, and to advance this technique toward clinical applications.  Despite the 
advancements made by these studies, many challenges remain before ultrasound-
enhanced delivery can become a realistic therapy.  To address some of these issues, the 
goals of this study were (i) to develop a measurement based on cavitation sound 
emissions to correlate with bioeffects for a means to predict and control intracellular 
uptake and loss of viability and (ii) to evaluate the ability of ultrasound to target 
intracellular delivery into endothelial and smooth muscle cells in viable ex vivo arteries 
for potential treatment of cardiovascular diseases and dysfunctions.  In addition, this 
study sought to exploit the underlying shear mechanism of ultrasound-enhanced delivery 
by (iii) developing a simplified device to expose cells to shear stress and cause 
intracellular uptake of molecules. 
 xx
 The first objective of this work was to relate a measurement of cavitation to 
ultrasound-induced bioeffects.  We sought to record and analyze the cavitation emissions 
while simultaneously measuring intracellular delivery and loss of cell viability mediated 
by cavitation in an in vitro cell suspension.  Analysis of recorded cavitation emissions 
was performed by deriving the frequency spectra of the sound and monitoring the 
features indicating cavitation. The frequency spectra of cavitation emissions were found 
to exhibit characteristic features of cavitation, including subharmonics, ultraharmonics, 
and increased broadband noise levels.  Concentrating on broadband noise, a common 
measure of inertial cavitation (i.e., cavitation associated with violent bubble implosions), 
we were able to monitor the kinetic activity of inertial cavitation.  Broadband noise was 
found to increase sharply during the first 20 milliseconds to a peak value and then 
decayed with a half-life of tens to hundreds of milliseconds until reaching a point of 
constancy.  From analysis of the kinetic behavior over a range of experimental and 
acoustic parameters, we proposed that cavitation activity was principally controlled by 
the initial number of bubbles capable of undergoing inertial cavitation (i.e., bubbles 
within the size range for inertial cavitation) and by the rate of destruction of bubbles by 
inertial cavitation. Furthermore, we analyzed cavitation while altering the acoustic and 
experimental parameters, including pressure, exposure time, frequency, microbubble 
concentration, and cell type, and measuring the cellular bioeffects, generating 350 data 
points.  Calculating the time integral of broadband noise provided a measure of the 
inertial cavitation dose that correlated strongly to intracellular uptake and loss of 
viability.  The inertial cavitation dose proved to be a unifying parameter that correlated to 
the bioeffects over the broad range of parameters tested.  The significance of this study is 
 xxi
that we have demonstrated that broadband noise can provide an appropriate measure of 
inertial cavitation activity and, more importantly, we have shown broadband noise 
measurements can improve the correlation with cellular bioeffects compared to other 
measures of cavitation (e.g., acoustic energy or sonoluminescence measurements). 
Therefore, we believe broadband noise can be used to predict and control bioeffects in 
the lab or potentially in the clinic. 
The second aim of this work was to evaluate intracellular drug delivery by 
ultrasound in viable arterial tissue for potential treatment of cardiovascular diseases and 
dysfunctions.  For these studies, we focused on intracellular delivery into endothelial and 
smooth muscle cells by exposing viable ex vivo porcine carotid arteries to ultrasound.  By 
analyzing the arteries using confocal microscopy, we found that ultrasound could cause 
targeted intracellular delivery to endothelial and smooth muscle cells and often caused 
loss of viability in the form of dead intact and denuded cells. Furthermore, quantification 
of bioeffects was used to determine the approximate acoustic energies required for a 
range of bioeffects. At low to intermediate ultrasound energy, ultrasound achieved 
targeted intracellular delivery into viable cells that represented 9 – 24% of exposed 
endothelial cells and also typically caused 7 - 25% endothelial cell death.  At high 
energy, intracellular delivery was targeted to smooth muscle cells, which further caused 
denuding or death of proximal endothelial cells.  Lastly, by experimentally testing intact 
arteries, we found that ultrasound can target delivery at near physiologic conditions.  This 
study represents the first known in-depth study that has evaluated intracellular uptake of 
molecules into viable tissue by ultrasound. 
 xxii
The last aim of this work sought to develop a simple device to expose in vitro 
cells to shear forces, thereby causing intracellular uptake.  By fabricating microchannels 
in Mylar® sheets with established micro-machining techniques, we designed a device that 
could force cells in suspension through microchannels, thereby exposing cells to high 
shear forces for short durations.  By evaluating channels of various dimensions and 
geometries, we found that shear generated at channel diameters of approximately 40-50 
μm and in a conical geometry yielded the best results, approximately 36% of cells with 
uptake and 80% viability.  We further found that this technique could deliver small 
molecules to large macromolecues (e.g., proteins) into cells.  Lastly, we designed a 
device that provided a quick, high-throughput method to deliver molecules into cells.  
The significance of this work is that we have developed a simple and inexpensive device 
that could be potentially used by the biological, medical, and biotechnology communities 
to cause intracellular delivery into cells. 
In summary, this thesis has advanced advancement the field of ultrasound-
enhanced delivery by (i) developing a measurement based on cavitation emissions, to 
correlate with ultrasound-mediated bioeffects, i.e., intracellular uptake and loss of 
viability and by (ii) evaluating the intracellular uptake into viable cells in tissue by 
ultrasound.  The correlation of cavitation measurements with bioeffects suggests possible 
laboratory and clinical applications in ultrasound-enhanced delivery of drugs and genes 
into cells.  By evaluating ultrasound-enhanced delivery in arterial tissue, we believe these 
findings indicate the approximate ultrasound energies for in vivo applications.  
Furthermore, this work suggests potential strategies for cardiovascular applications to 
deliver molecules into endothelial or smooth muscle cells.  Lastly, by using shear forces 
 xxiii
generated in microchannels, we have fabricated a simple and inexpensive device to cause 
intracellular uptake of small and large molecules into in vitro cells.  We believe this 
device has the capability to be used in the lab, clinic, or plant to deliver bioactive 






 With escalating advancements in new therapeutic drugs in recent decades, 
increasing attention has been focused on methods to deliver drugs in more efficient and 
effective manners (Langer 1998; Saltzman 2001).  A large amount of research has been 
performed in drug delivery to improve administration, targeting, controlled release, 
effectiveness, and efficiency of drugs by chemical modifications to the drug (e.g., 
antibodies, proteins, polymers) (McCarron et al. 2005; Sapra et al. 2005; Veronese and 
Pasut 2005), the use of controlled release systems (e.g., polymeric degradation and 
diffusion, liposomal vesicles) (Chien 1992; Stubbe et al. 2004), and novel mechanical or 
electrical mechanisms (e.g., electroporation, iontophoresis, microneedles) (Batheja et al. 
2006; Heller et al. 2005; Prausnitz 2004).  Efficiently targeting specific cells and 
permeating the cell’s natural regulating barriers (e.g., cellular membrane or nuclear 
membrane) to allow intra- and extra-cellular molecular transport remains a difficult 
challenge and limits the effectiveness and potential of many drugs and gene therapy 
treatments (Panyam and Labhasetwar 2004; Stein and Lieb 1986).  A general method to 
deliver therapeutic agents in a more safe and effective manner would provide a great 
benefit in a broad range of drug delivery applications to increase the efficacy of current 
drugs, lower administrating costs, decrease side effects, and promote future gene therapy 
and drug design.  A potential remedy to these difficulties in drug delivery is the method 
of ultrasound-enhanced drug delivery, a novel technique that offers the potential to 
efficiently deliver drugs to highly targeted regions of the body by a non-invasive method. 
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 Ultrasound-enhanced drug delivery research is at the frontier of drug delivery  and 
aims to develop a novel method to increase targeting to specific areas of the body, 
increase delivery efficiency, and release drugs in controlled doses (Mitragotri 2005).  As 
a mechanical method that increases drug delivery targeting, ultrasound has the potential 
to be applied to a broad range of applications from chemotherapy treatment at specific 
tumor locations (Tachibana 2004) to treating atherosclerosis at the site of the disease 
(Bekeredjian et al. 2005).  By exploiting the local mechanical and possibly chemical 
effects (e.g., high local temperatures and pressures, microstreaming, shear flow, and free 
radical formation) associated with the acoustic cavitation induced by pressure transients 
of ultrasound, this method is able to reversibly permeabilize the cells’ regulating barrier 
to its extracellular environment and allow passive diffusion of extracellular compounds 
into the cell (Miller et al. 1996).  The potential of ultrasound-enhanced drug delivery has 
been mainly shown in systems of in vitro cell suspensions, with encouraging results 
demonstrating improved delivery of DNA for gene therapy (Tsutsui et al. 2004) and 
loading of cells to equilibrium with the extracellular concentration of molecules of 
interest (e.g. calcein or fluorescent dextrans) (Guzman et al. 2002).  Furthermore, 
ultrasound-enhanced drug delivery has also been studied in ex vivo tissue and in vivo 
animal models as a means to deliver therapeutic plasmids (Bekeredjian et al. 2005).   
One of the greatest challenges with the application of ultrasound-enhanced drug 
delivery is the prediction of bioeffects based on the acoustic and experimental 
parameters.  A means to control bioeffects based on a measurement of the input or output 
parameters would allow for feedback control by clinicians to optimize the amount of 
uptake and loss of viability for particular applications.  The measurement of cavitation by 
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analyzing the acoustic emissions from cavitation and correlating this measurement with 
bioeffects is the scope of the first part of this thesis.  Determining the capabilities of 
cavitation in systems beyond simple cells suspensions in ex vivo or in vivo tissue is also 
essential to the development of ultrasound-enhanced drug delivery.  The second portion 
of this thesis investigates delivery into ex vivo arterial tissue to understand the effects and 
mechanism of cavitation.  Based on the commonly held belief that shear forces from fluid 
flow is the cause of bioeffects by ultrasound-mediated cavitation, the last portion of this 
thesis investigates the use of microfluidic channels as a means to impart high shear forces 









In recent years, novel and improved drug delivery systems have become a 
heightened focus for pharmaceutical and biomedical companies and academic research.   
Sales of advanced drug delivery systems in the U.S. have reached nearly $20 billion 
annually (Langer 2001).  Research on improving drug delivery systems is aimed at 
enhancing the administration of drugs in safe and non-invasive manners, improving the 
targeting or effectiveness to specific tissues or cells, increasing the solubility, and 
controlling the release of drugs (Rosen and Abribat 2005).  The range of current research 
in drug delivery systems spans chemical modifications of drugs, new particles for 
transport of drugs, improved polymeric release mechanisms, and new mechanical and 
electrical methods (Langer 1998).   
Chemical modifications to drugs can enhance the targeting by antibody or 
microparticle linkages (McCarron et al. 2005), improve pharmacokinetics and solubility 
by attachment of degradable synthetic polymers (Aliabadi and Lavasanifar 2006; Duncan 
and Spreafico 1994), or alter immunogenicty of the drug by protein engineering and 
attachment of polymers such as polyethylene glycol to the drug (Veronese and Pasut 
2005).  Chemical alterations to drugs can also include creating microparticle or colloidal 
carriers for drugs.  These carriers typically consist of proteins, lipids, or synthetic 
polymers (e.g., liposomes) (Gupta et al. 2005; Hofheinz et al. 2005) and aim to improve 
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systemic transport of the drug, create anti-immunogenic particles, improve targeting, or 
enhance transport through the lipid-based cellular membrane.   
Controlled release delivery spans a wide variety of engineered systems, but in 
general, the goal is to administer drugs in controlled dosage levels and to avoid the peaks 
and valleys in systemic drug concentrations, which are common in many conventional 
methods (Conti et al. 2000).  This is particularly important since many drugs must be 
above a certain concentration level threshold to be effective and below a certain level to 
avoid being toxic to the patient (Chien 1992).   
Novel mechanical and electrical methods include techniques to improve 
administration.  These include iontophoresis, electrically driving molecules across tissues 
(Batheja et al. 2006); electroporation, permeabilizing the impeding cell membrane (Gehl 
2003); magnetic particles, carrying and releasing drugs under magnectic fields (Edelman 
et al. 1985); high velocity particles or jets, transdermal delivery by impacting the skin 
with high velocity injections (Burkoth et al. 1999); and microneedle injections, 
transdermal delivery by painless microscopic needles (Prausnitz 2004).   
Ultrasound-enhanced drug delivery falls into the classification of novel 
mechanical methods.  These novel techniques to deliver drugs have the potential to 
improve not only the market of current drugs, but also to promote future drug design and 
provide the necessary means to deliver the latest complex agents such as genetic material 




 Sound is propagating pressure waves through a medium such as air or water at 
frequencies perceived by humans.  Generally, mechanical vibrations create sound or 
pressure waves in an elastic medium, transferring energy into the medium and to any 
objects the sounds contact.  Ultrasound is defined as sound in frequency ranges above the 
audible range of humans.  The typical human range for audible sound is from 4 Hz to 20 
kHz; therefore, ultrasound is classified as sound at frequencies above 20 kHz.  Typically, 
ultrasound is generated from transducers composed of piezoelectric materials such as 
quartz or certain ceramics that resonate when electricity is passed through the material.  
These vibrations of the piezoelectric material convert electrical energy to mechanical 
energy in the form of high frequency sound (Pierce 1981).  A common purpose of 
ultrasound is cavitation production for the application of imaging, cleaning, initiating 
chemical reactions, drug delivery, destruction of kidney stones, or surgically destroying 
cells (Apfel 1997). 
Acoustic cavitation 
 Acoustic cavitation is defined as the bubble formation and/or oscillation of gas 
bubbles in liquid due to rapid variations in pressure caused by ultrasonic waves.   
Cavitation induced from acoustical activity is typically a result of either (1) liquid vapor 
that forms as a result of the local pressure falling below the vapor pressure of the liquid, 
(2) dissolved gases that come out of solution due to the low local pressures, or (3) pre-
existing stabilized gas bubbles present in the liquid (Apfel 1997).   
Cavitation can be further classified as either stable or inertial cavitation (also 
known as transient cavitation) based on the oscillations the bubbles undergo.  At low 
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pressures, the bubbles oscillate in a stable manner for many cycles, hence termed stable 
cavitation.  However, high-pressure oscillation can cause large fluctuations in the bubble 
size and can lead to a violent implosion of the bubble above a certain pressure threshold; 
this type of cavitation is termed inertial cavitation.  The type of cavitation has drastically 
different local effects from the lesser impacting effects of stable cavitation to the more 
intriguing and intense activity of inertial cavitation (Leighton 1994). 
The implosion of inertial cavitation occurs so quickly that it causes compression 
of the gas at near adiabatic conditions (Leighton 1994).  As a result, the imploding bubble 
reaches extremely high temperatures and pressures (i.e, >5000oC and > 500 atm) (Flint 
and Suslick 1991; Suslick 1990).  These intense conditions can cause the formation of 
free radicals and a variety of chemical reactions that have been extensively researched for 
applications in the chemical industry (Suslick 1990).  These sonochemical reactions have 
also been shown to cause light emissions, a phenomenon referred to as sonoluminescence 
(Crum 1994).    
With bubbles in either stable or inertial cavitation, the surrounding liquid forms 
local streaming and mixing, creating local shear flow (Acoustical Society of America 
2002).  When a bubble collapses near an object, the collapse can occur non-uniformly 
and force a stream of liquid through the bubble towards the impinging object.  These 
local small jets of water are called microstreaming and can cause intense mixing, high 
local shear flow, and damage to the objects (Lauterborn and Ohl 1997).  
Just as the piezoelectric source vibrates to create ultrasound, the vibrations of the 
bubbles further cause their own sound emissions.  The resonant frequency of a bubble is 
determined by its size and the viscosity of the surrounding liquid (Allen et al. 1997).  
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When sound is applied to a bubble at its resonant frequency (e.g., ~ 2 MHz for the mean 
size of Optison® bubbles), the bubble oscillates linearly and in phase with the pressure 
fluctuations of sound, emitting sound at the same frequency as the driving frequency.  
However, when the frequency of sound does not match the resonant frequency of the 
bubble, the bubble will oscillate non-linearly or out of phase with the pressure 
fluctuation.  These non-linear vibrations can produce sound at frequencies other than the 
driving frequency, often emitting sound at subharmonics or ultraharmonics of the driving 
frequency (i.e, ½f, 3/2f, 2f, 5/2f,3f, etc) (Leighton 1994).  These emissions of sound at 
the driving frequency and subsequent harmonics are further superimposed onto a level of 
broadband noise caused by erratic oscillations and the violent implosion of inertial 
cavitation (Neppiras 1968).  Cavitation emissions are often studied to characterize the 
cavitation activity and used in an attempt to monitor the amount and quality of cavitation 
(Chen et al. 2003; Neppiras 1980). 
The combination of these local effects of acoustic cavitation and ultrasound’s 
ability to be applied in a focused and non-invasive manner make ultrasound a favorable 
tool for the medical industry.  Using one or a combination of these local effects caused by 
ultrasound-induced cavitation, a variety of current medical applications can be achieved, 
including imaging, heating tissue, tissue destruction, or lithotripsy, and future 
applications such as ultrasound-enhanced drug delivery are being avidly pursued.  
Ultrasound in Current Medical Applications 
Ultrasound has a long history of use as a diagnostic and therapeutic instrument in 
the medical industry for applications in medical imaging, physical therapy, and 
lithotripsy.  The uses of ultrasound range from conditions with minimal bodily impact for 
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medical imaging (e.g., myocardial diagnosis and fetus development) (Beach 1992) to 
conditions with high bodily impact for surgery such as lithotripsy (Madersbacher and 
Marberger 2003), which is the destruction of kidney stones and tissue by ultrasonic 
cavitation. 
Ultrasound was first used as a medical tool in physical therapy.  Ultrasound’s 
ability to heat tissues and to be focused non-invasively in the body was first discovered in 
the 1930s and as a means to heat inner body tissues.  Ultrasound has since developed into 
an accepted tool in the field of physical therapy for heating specific tissues (Ng and Liu 
2002).  The application of ultrasound to heat tissues has been further extended and 
researched to treat some cancers by heating tumors to help kill cancerous cells 
(Madersbacher et al. 1995).  
The use of ultrasound as a diagnostic tool for imaging did not develop until the 
late 1940s and 1950s.  When sound contacts another object or a medium with different 
physical properties, sound is not only transferred into the next medium but is also 
reflected back towards the source.  Using this principle, imaging of the interior of the 
human body is possible by applying this pulse-echo technique, a method similar to the 
naval reconnaissance tool know as SONAR and the echolocation technique used by bats, 
dolphins and whales (Ng and Liu 2002).  As ultrasound is non-invasively focused into the 
body, sound reflections are sent back to the source due to the different physical 
characteristics of tissue, bone, blood and other matter.  These reflections are then 
recorded and analyzed to form distinctions between tissues and organs and further 
processed to generate an image.  With vastly improving imaging resolution and the 
development of 3-D imaging over the last 50 years, ultrasound has become an 
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exceptionally popular diagnostic tool in the medical community, particularly for non-
invasively monitoring fetus development in obstetrics and diagnosing myocardial 
abnormalities (Hollis and Thilaganathan 2001; Mittle et al. 2003). 
In the past few decades, other improvements to imaging have been made through 
the use of contrast agents.  Contrast agents are stabilized gas bubbles typically consisting 
of a protein- (i.e. albumin) or lipid- based shells filled with an inert gas (i.e., 
perflurocarbon gas), such as Optison® or Definity® (Goldberg et al. 1994; Miller and 
Nanda 2004).  Contrast agents are intravenously introduced into the body’s blood 
circulation.  When imaging the circulation of blood in the heart or blood vessels, the 
bubbles serve as echogenic agents that produce more acoustic reflections to yield 
increased contrast between the blood and surrounding tissues (Forsberg et al. 2000).  
These contrast agents are widely used in myocardial imaging to delineate the endocardial 
borders in echocardiograms (Mittle et al. 2003) and give an improved image of muscle 
contractions and heart valves (Rosenzweig et al. 2001).   
Ultrasound can also be used in high-energy conditions such as removing kidney 
stones by extracorpeal shock wave lithotripsy (Coleman and Saunders 1993).  
Approximately 75% of treated kidney stones are treated with lithotripsy (Holmes and 
Whitfield 1991).  Using a spectrum of high-intensity acoustic waves, relative to 
diagnostic and physical therapy levels of ultrasound, acoustic energy is focused at the 
kidney stones to create intense inertial cavitation that destroys or breaks apart the kidney 
stones and allow them to be passed more easily by the patient (Coleman and Saunders 
1993). 
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 Ultrasound has developed into a tremendously useful tool for the medical 
community in a broad range of applications due to its non-invasive nature, ability to be 
targeted into the body, and wide range of intensity levels to impact the body.  Exposure 
intensity levels of ultrasound in medical applications range from <0.5 W/cm2 in 
diagnostic imaging, 0.5-3 W/cm2 in therapeutic applications, and >10 W/cm2 in 
lithotripsy treatments (Ng and Liu 2002).  As ultrasound has become an established 
modality in a number of treatments, further novel applications of ultrasound are 
continually being explored and researched.  
Ultrasound in Drug Delivery 
 The latest research has found ultrasound to be valuable in interesting applications 
for drug delivery.  The remarkable benefits of ultrasound in drug delivery include its 
ability to be applied in non-invasive or minimally invasive manners and focused to affect 
only the specific tissues or cells of interest.  As a mechanical method, in contrast to a 
chemical modification, ultrasound has the potential to be applied to a wide range of 
current and future drugs.  By exploiting the local effects of acoustic cavitation induced by 
ultrasound, cavitation can cause reversible permeation across cell membranes, allowing 
the intracellular transport of molecules into the cell (Cooke 2000; Mitragotri 2005), 
and/or cause release from drug carriers such as micelles, liposomes, microbubbles, and 
polymers (Marin et al. 2002; Rapoport 2004; Unger et al. 2004).   
 The earliest application and research of ultrasound-enhanced drug delivery was a 
method to promote transdermal drug delivery of hydrocortisone ointment into inflamed 
tissues (Tyle and Agrawala 1989).  Transdermal drug delivery is an avidly pursued 
method due to its potential ease of administration and its ability to bypass the 
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gastrointestinal system’s harsh metabolism (Langer 1990).  However, transdermal drug 
delivery remains a difficult challenge due to the daunting task of crossing the 
impermeable barrier presented by the stratum corneum, the outer most layer of dead skin 
(Edwards, 1994).  Research of ultrasound for transdermal drug delivery, a phenomenon 
known as sonophoresis or phonophoresis, has been attempted for low molecular weight 
drugs and proteins such as insulin (Mitragotri et al. 1995).  Ultrasound has been shown to 
increase the permeability of the skin by a mechanism believed to involve cavitation at the 
skin’s surface, which can disorganize the stratum corneum layer, thereby promoting 
molecular transport across the layer of skin (Mitragotri et al. 1995).  Even though early 
attempts at promoting transdermal drug delivery with megahertz-frequency ultrasound 
met with limited success, more recent work in the kilohertz range has effectively 
enhanced delivery of a range of different compounds (Barry 2001). 
 Understanding the local effects of cavitation induced by ultrasound has led studies 
to exploit these effects to cause cell permeabilization, allowing increased diffusion of 
extracellular compounds into the cell.  Many researchers have investigated cavitation in 
terms of causing cell lysis and damage in erythrocytes (Daniels et al. 1995; Everbach et 
al. 1997) and other cell suspension systems (Brayman et al. 1999; Miller and Quddus 
2001) to identify and prevent the negative effects ultrasound may cause in diagnostic 
treatments.  However, other investigators have chosen to examine cavitation in a more 
positive sense and have explored the use of acoustically induced cavitation to cause 
reversible permeabilization of the cell membrane for therapeutic drug and gene delivery 
(Amabile et al. 2001; Guzman et al. 2001).  The cell membrane is an arduous barrier for 
drug delivery (Stein and Lieb 1986), and various engineered techniques, including 
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ultrasound-enhanced drug delivery, are being explored to increase diffusion of drugs 
across the cellular membrane. 
 Acoustic cavitation’s mechanism of cellular damage is hypothesized to be mainly 
a mechanical process in which the induced microstreaming and shear flow, namely from 
inertial cavitation, causes local damage to the cell (Miller et al. 1996; Schlicher et al. 
2006; Wu et al. 2002).  Others have also shown that the chemical effects of cavitation, 
such as free radical formation, can cause further bioeffects, hypothetically by cellular 
membrane destruction or inducing other cellular pathways such as apoptosis (Feril et al. 
2003; Lagneaux et al. 2002).  The ability of cavitation to cause local damage to the cell 
can potentially be a beneficial tool if the cellular damage allows increased molecular 
transport across the cell membrane and if the cell is able to repair damage, remain viable, 
and maintain normal metabolism and function.  
 Previous research has shown the potential of ultrasound-enhanced drug and gene 
delivery in cell suspension systems and cell monolayers, typically utilizing fluorescent 
molecules to monitor the molecular uptake (Chen et al. 2003; Greenleaf et al. 1998; 
Guzman et al. 2001; Guzman et al. 2002).  Results of these experiments have been 
encouraging as they have shown its possible to cause reversible permeation, intracellular 
uptake is capable for molecular sizes up to 464 kDa, and intracellular uptake reaches 
equilibrium with extracellular concentrations (Guzman et al. 2002).  Further research has 
shown positive results for increasing the uptake of genetic material and may be used to 
facilitate gene therapy treatments in combination with adenoviral or liposomal techniques 
(Beeri et al. 2002; Koch et al. 2000).   
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 A large portion of research with ultrasound in in vivo animal models, have 
investigated this technique for gene therapy in the cardiovascular system.  Many studies 
have shown positive results of delivery of therapeutic genes and tissue responses.  This 
research has mostly focused on reducing or preventing neointimal formation in 
atherosclerotic plaques or promoting angiogenesis for the treatment of ischemic heart or 
peripheral injury (Bekeredjian et al. 2005).  Others have also shown positive transfection 
results by ultrasound in in vivo tissues such as skeletal muscle (Lu et al. 2003), kidney 
(Koike et al. 2005), and liver (Kondo et al. 2004) for various applications.  However, few 
studies have focused on the delivery of small molecules or proteins by ultrasound in vivo 
(Mitragotri 2005).  
 The current limitation of ultrasound-enhanced delivery is the low fraction of cells 
with uptake at low acoustic energies and the high loss of viability at high acoustic 
energies.  However, in some treatments, the loss of viability may be a desirable effect, 
such as in treating cancerous cells or tumors (Kennedy 2005) or destroying fat cells (Pine 
et al. 2003).  The loss of viability has been shown to inversely correlate with the amount 
of uptake.  Many studies have attempted to correlate the bioeffects (i.e., uptake and loss 
of viability) with  aspects of cavitation or the acoustic parameters (Cochran and Prausnitz 
2001; Guzman et al. 2001; Sundaram et al. 2003).     
 Research has also focused on using ultrasound to control drug release by using 
acoustic cavitation as a triggering mechanism.  By using micelles, liposomes, 
microbubbles, or polymers that encapsulate the drug, the mechanical or chemical effects 
induced by ultrasound have been shown to trigger drug release in a controlled manner 
(Marin et al. 2002; Rapoport 2004; Unger et al. 2004).   This method would be especially 
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beneficial to cause targeted release by exploiting ultrasound’s ability to be focused into 
the body.  If further used in combination with cell permeation, these modalities may lead 
to a powerful technique for controlling drug release and targeting specific cells for drug 
delivery in a non-invasive manner. 
Cardiovascular Drug Delivery 
 Cardiovascular disease (CVD) is currently one of the leading causes of death, 
resulting in nearly 17 million deaths per year worldwide (Smith et al. 2004).  In the U.S. 
alone, CVD affects nearly 70 million people, accounts for 900,000 or 40% of the deaths 
per year, and remains the leading cause of death.  Projected economic costs are estimated 
at $400 billion for 2006 in the U.S (Thom et al. 2006).  CVD includes coronary and 
peripheral heart disease, hypercholesterolemia, and hypertension that can lead to heart 
attack or stroke.  Other vascular dysfunctions include restenosis post percutaneous 
interventions, myocardial and peripheral ischemia, and vascular angiogenesis in 
tumorous cancers. 
 Blood vessels, i.e., arteries or veins, are composed of three distinct layers, known 
as the intima, media, and adventitia (Fig 2.1) (Davis et al. 2003).  The intima consists of a 
monolayer of endothelial cells that rest upon an elastin protein matrix, the internal elastic 
lamina.  The muscular portion of the vessel, known as the media, consists of smooth 
muscle cells that mainly serve to exert muscular contraction or relaxation.  Lastly, the 
adventitia mainly consists of connective tissue of collagen but also contains fibroblasts, 





Figure 2.1:  The vascular anatomy (Davis et al. 2003) 
 
 In the past, the endothelium was viewed only as a cell layer to provide a 
mechanical, non-thrombogenic barrier.  The endothelium is now known to be a critical 
mediator in a number of chemical pathways that maintain homeostasis and vascular tone, 
regulate thrombosis and vascular permeability, mediate inflammatory responses, control 
smooth muscle cell proliferation, and initiate angiogenesis (Belanger 1990).  Endothelial 
dysfunction occurs when endothelial homeostasis is disturbed due to pathological 
stresses, such as increased oxidative stress, hyperlipidemia, inflammation, and 
mechanical injury.  Endothelial dysfunction can lead to a host of detrimental effects, such 
as an imbalance of vasodilator and vasoconstrictor agents (e.g., nitric oxide and 
prostacylcin, angiotesin II, and thromboxane), increased platelet adhesion, macrophage 
recruitment, and uncontrolled smooth muscle cell proliferation (Cines et al. 1998).  The 
pathological results may be atherosclerotic lesions, hypertension, or re-narrowing of the 
artery in the case of restenosis (Cines et al. 1998).  In cancerous tumors, an imbalance is 
caused by the over-production of angiogenic factors such as vascular endothelial growth 
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factor (VEGF).  This imbalance leads to an uncontrolled and tortuous vascular system 
that allows tumors to grow to larger sizes and metastasize (Hanahan and Weinberg 2000; 
Sato 2003).  In contrast, myocardial or peripheral ischemia is a condition caused by 
insufficient blood supply due to failing blood vessels from injury or disease (Madeddu 
2005). 
 Due to the critical role of endothelial cells and smooth muscle cells in controlling 
vascular functions and dysfunction in a number of pathological conditions (Cines et al. 
1998), targeted drug and gene therapy to the vascular endothelium and media has 
increasingly become a focus for treating cardiovascular diseases and dysfunctions (Cooke 
2000; Feldman and Steg 1997; Melo et al. 2004; Quarck and Holvoet 2004).  In many of 
these ailments, it is desired to have drug or gene delivery to the specific diseased site in 
order to locally treat the area or lesion while avoiding harsh or toxic systemic side effects.  
Currently, many drug delivery techniques, such as drug-elutings stents (Gershlick 2005), 
catheter-based delivery systems (Sharif et al. 2004), viral vectors, targeted liposomes 
(Quarck and Holvoet 2004), and targeted microbubbles (Kipshidze et al. 2005), are being 
studied to cause targeted drug or gene delivery to specific diseased sites in the 
cardiovascular system. 
 Current gene therapy research in the cardiovascular system is aimed at genetically 
manipulating the endothelium or smooth muscle cells by increasing protein expression or 
blocking protein expression of certain factors in order to reestablish a chemical balance 
and reaffirm homeostasis (e.g., eNOS or E2F decoy), promote angiogenesis (e.g.., VEGF 
or FGF) (Quarck and Holvoet 2004), or decrease or kill vasculature in tumors (e.g.., 
Caspase-9) (Song et al. 2005; Tozer et al. 2005).  However, most current techniques lack 
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either the effectiveness or specificity to adequately treat these disorders while safely 
administering the therapeutic agent and avoiding toxic systemic effects.  A safe and 
effective method to target delivery of genes to the specific disease site in the vasculature 
would greatly benefit treatment of cardiovascular diseases and dysfunctions. 
 A novel approach to targeting drug and gene administration is the method of 
ultrasound-enhanced delivery.  The vascular endothelium is an attractive target for 
ultrasound-enhanced delivery because cavitation, often necessary in the mechanism of  
delivery by ultrasound, can be readily produced in the vasculature, as currently performed 
for diagnostic imaging (Correas et al. 2001).  Moreover, cavitation is expected to have 
limited effects beyond cells layers directly experiencing cavitation activity, and the 
endothelium is the first point of contact to cavitation activity (Hwang et al. 2005).  A 
number of researchers are currently studying ultrasound-enhanced gene therapy for 
cardiovascular disorders to control intimal hyperplasia, restore vascular function, or 
promote angiogenesis.   These studies have shown expression of reporter plasmids as 
well as plasmids with a therapeutic purpose and delivery of drugs and proteins 
(Bekeredjian et al. 2005).  Clinical potential of this method has been shown by causing 
protein expression by plasmid DNA (Amabile et al. 2001; Huber et al. 2003; Taniyama et 
al. 2002; Teupe et al. 2002) or blocking specific proteins by gene blocking siRNA (Miura 
et al. 2002) and decoy oligonucleotides (Hashiya et al. 2004).  A recognized limitation of 
this method is the low number of cells with drug uptake or gene expression (Bekeredjian 
et al. 2005).  However, few studies have been directed at analyzing the uptake efficiency 
and imaging the bioeffects, i.e., intracellular uptake and loss of viability, caused by 
ultrasound-enhanced delivery in viable tissue (Mitragotri 2005).  It is important to know 
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the uptake efficiency at different ultrasound energies in order to design and apply this 
technique for drug or gene delivery applications. 
Shear-Induced Bioeffects 
 Biological research in industry and academia rely on techniques including 
electroporation (Gehl 2003), liposomes (Goyal et al. 2005; Simoes et al. 2005), viral 
vectors (Young et al. 2006), microinjection (Jensen et al. 2003), cell penetrating proteins 
(Kerkis et al. 2006), and other emerging technologies to deliver small molecules to 
macromolecules intracellularly for in vitro studies.  These studies aim to deliver 
molecules such as genetic material to alter protein expression, macromolecules to alter 
cellular processes, or labeling probes to stain cell organelles or structures.  Establishing a 
means to uniformly cause poration in cells by a simple and effective means, would have 
many applications in in vitro procedures. 
Cellular membrane poration by mechanical forces has been studied using a 
variety of techniques to bypass the barrier imposed by the membrane for intracellular 
delivery and to understand the cellular response to mechanical injury.  Membrane tension 
is believed to be the central event by which these mechanical means cause poration or 
wounds in the lipid bilayer cell membrane (Lokhandwalla and Sturtevant 2001). 
 The first studies on pore formation by membrane tension were performed using 
osmotic swelling or micropipetting techniques on red blood cells.  These studies found 
that membrane poration and subsequently cell lysis in red blood cells, which lack the 
ability to repair actively, occur at the critical areal strain of 2-3% and the critical tension 
of 10 mN/m3 (Evans et al. 1976).  Beyond directly inducing membrane tension, many 
techniques have used shear stress to generate membrane tension and cause poration.  It is 
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theorized by Lokhandwalla et al. (Lokhandwalla and Sturtevant 2001) that shear stress 
from shock waves or cavitation cause cell deformation due to extensional flow, causing 
tension and poration of the cell membrane.  The techniques to induce shear forces upon 
the cell include fluid flow in viscometers or syringes (Clarke and McNeil 1992), cell 
scraping (McNeil et al. 1984), shock waves by lasers (Doukas and Kollias 2004; Kodama 
et al. 2002; Mulholland et al. 1999) or ultrasound (Lokhandwalla and Sturtevant 2001), 
and cavitation activity induced by lasers or ultrasound (Miller et al. 1996; Ohl and 
Wolfrum 2003; Rau et al. 2004).  Furthermore, it is suspected that cell shear is a critical 
event in injury (i.e., tramatic brain injury) leading to cell death or dysfunction (Prado et 
al. 2005).  From these studies, it is clear that shear stress is a powerful mediator of cell 





MATERIAL AND METHODS 
 
Measurement and Correlation of Acoustic Cavitation with Cellular Bioeffects 
Cell sample preparation 
Cell culture and preparation was performed as described by Guzman et al. (2001).  
In brief, human prostate cancer cells (DU145, American Type Culture Collection, 
Manassas, VA, USA, item no. HTB-81) were cultured as monolayers in a humidified 
atmosphere of 95% air and 5% CO2 at 37oC in RMPI-1640 medium, supplemented with 
100 μg/ml penicillin-streptomycin (Cellgro, Mediatech, Herndon, VA, USA) and 10% 
(v/v) heat inactivated fetal bovine serum (Atlanta Biologicals, Atlanta, GA, USA).  
Human aortic smooth muscle cells (AoSMC, Cambrex, East Rutherford, NJ, USA, 
catalog no. CC-2572, lot no. 2FO653) were initiated from a cryopreserved stock and 
harvested at passage seven prior to each experiment.  They were cultured as monolayers 
in a humidified atmosphere of 95% air and 5% CO2 at 37oC in MCDB-131 medium, 
supplemented with 100 μg/ml penicillin-streptomycin and 10% (v/v) heat inactivated 
fetal bovine serum.  Both cell types were harvested by trypsin/EDTA (Cellgro) digestion, 
washed and resuspended in pure RPMI for DU145 cells and pure MCDB-131 for 
AoSMC. 
Prior to ultrasound exposure, samples were prepared at a cell concentration of 106 
cells/ml, a calcein concentration of 10 μM and Optison® concentrations of 0.25% v/v (~ 
1.6 x 106 bubble/ml), 1.7% v/v (~ 1.1 x 107 bubble/ml) and 14.3% v/v (~ 9.3 x 107 
bubble/ml).  Calcein (623 Da, radius = 0.6 nm; Molecular Probes, Eugene, OR, USA, 
 22
catalog no. C481), a green fluorescent molecule that cannot cross intact cell membranes, 
was used to quantify molecular uptake into viable cells.  Optison® (Mallinckrodt, St. 
Louis, MO, USA. catalog no. 2707-03) is a suspension of perfluorcarbon gas bubbles 
stabilized with denatured human albumin that was used to serve as nuclei to promote 
cavitation activity.   
Ultrasound apparatus 
Ultrasound was produced using an immersible, focused, piezoceramic transducer 
(Sonic Concepts, Woodinville, WA, USA, model no. H-101), supplied with two different 
matching resistance networks allowing production of sound at 1.1 MHz (vicinity of 
fundamental node) and 3.1 MHz (vicinity of third harmonic).  The transducer had a 
diameter of 70 mm, a 52 mm focal length and a 1.5 mm focal width at half-amplitude (-6 
dB).   
A sinusoidal waveform was produced by two programmable waveform generators 
(Standford Research Instruments, Sunnyvale, CA, USA, model no. DS345 and Agilent, 
Austin, TX, USA, model no. 33120A) used in conjunction to control pulse length, 
frequency and peak-to-peak voltage.  The sinusoidal waveform was then amplified by a 
RF broadband power amplifier (Electronic Navigation Industries, Rochester, NY, USA, 
model no. 3100LA) before passing through a matching network and then, finally, 
controlling the response of the transducer.   
The transducer was housed in a polycarbonate tank (30.5 x 29 x 37 cm) 
containing approximately 26 l of deionized, distilled and partially degassed water at room 
temperature, 22-23 oC.  A 5-cm thick acoustic absorber (SC-501 Acoustic Rubber, Sonic 
Concepts) was mounted opposite the transducer to minimize standing-wave formation.  A 
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three-axis positioning system (10 μm resolution, Velmex, Bloomfield, NY, USA) was 
mounted on top of the tank to position samples and a hydrophone at desired locations in 
the tank.  A PVDF membrane hydrophone (NTR Systems, Seattle, WA, USA, model no. 
MHA200A) was used to measure spatial-peak-temporal-peak negative pressure in order 
to map and calibrate the acoustic field produced by the transducer versus the peak-to-
peak voltage signal provided by the function generator. 
Experimental protocol 
Prior to every experiment, the desired sample placement in the acoustic field was 
found using the PVDF membrane hydrophone.  This location was approximately 1 cm 
and 0.5 cm out of the ultrasound’s focus towards the transducer for 1.1 and 3.1 MHz, 
respectively.  The acoustic pressure was calibrated versus the peak-to-peak voltage of the 
signal created by the function generator, using the PVDF membrane hydrophone at the 
desired location.  These out-of-focus locations had a broader acoustic beam than at the 
focus, approximately 10.4 mm and 2.4 mm wide at half-amplitude (-6 dB) for 1.1 and 3.1 
MHz, respectively.  This broader acoustic beam was favorable to have a more uniform 
acoustic exposure across the sample to reduce “dead zones” where cells or microbubbles 
were not exposed uniformly.  In addition to the broad exposure zone, vigorous mixing 
caused by cavitation during ultrasound exposure further enabled a more uniform 
exposure of all cells. 
Samples were placed within chambers constructed from the bulb of polyethylene 
transfer pipets (Samaco, San Fernando, CA, USA, cat. no. 293).  The bulb was cut from 
the transfer pipet approximately 3 mm from the top of the bulb.  At the other end, the 
bulb had a small hollow stub that was cut and filled with silicone rubber sealant (Dow 
 24
Corning, Midland, MI, USA) to prevent entrapment of the sample solution.  The final 
dimensions of the approximately cylindrical sample chamber were 1.4 cm in height and 
0.6 cm in diameter. 
A sample solution was slowly aliquoted via a 3-ml syringe (Becton Dickinson, 
Franklin Lakes, NJ, USA) with a 22-gauge needle (Perkin Elmer, Foster City, CA, USA) 
into a sample chamber, while making sure completely to fill the chamber, without air 
bubbles.  A metal rod was immediately inserted into the open end of the sample chamber 
and then attached to the three-axis positioning system, placing the sample in the desired 
location as determined by the hydrophone.  After sample placement, the computer 
program was initiated to record hydrophone output and the exposure was begun by 
triggering the function generator with the desired settings.  Exposures were performed at 
a burst length of 1 ms, 1% duty cycle (i.e., 10 pulses per second); pressures of 0.5, 0.8, 
1.2, 1.7 and 2 MPa; total exposure times of 3, 10, 30, 100, 300, 1000 and 3000 ms; and 
frequencies of 1.1 and 3.1 MHz.  Total exposure time is the amount of time a sample was 
exposed to ultrasound, calculated by multiplying the number of bursts times the burst 
length.  After ultrasound exposure, samples were immediately transferred into 1.5 ml 
microcentrifuge tubes (Eppendorf, Brinkman, Westbury, NY, USA) and allowed to 
“recover” for 5 min at room temperature.  Samples in microcentrifuge tubes were then 
placed on ice and allowed to incubate until all samples had been exposed (1 – 2 h).   
After all samples had been exposed, samples were washed with PBS (Cellgro) 
and centrifuged (800 x G, 3 min, Eppendorf 5415C, Brinkman, Westbury, NY, USA) 
three times to remove extracellular calcein in the supernatant.  The subsequent cell pellets 
were resuspended in a final volume of 205 μl of PBS containing 2 μg/ml of propidium 
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iodide (Molecular Probes, catalog no. P-1304), a viability marker that stains nonviable 
cells with red fluorescence. 
Quantification of bioeffects 
Flow cytometry was used to determine molecular uptake, i.e., fraction of cells 
containing intracellular calcein, and loss of cell viability by detecting the fluorescence 
intensity from calcein and propidium iodide, respectively, on a cell-by-cell basis.  A BD 
LSR benchtop flow cytometer (BD Biosciences, San Jose, CA, USA) was used to 
measure the fluorescence of cells with calcein uptake (FITC fluorescence, 530/28 nm 
bandpass filter) and to distinguish viable from nonviable cells by the red fluorescence of 
propidium iodide (Per CP fluorescence, 670 nm longpass filter).  Typical analyses 
sampled approximately 10000 cells.  The viability of a sonicated sample compared with a 
“sham” sonicated cell population, was determined by accounting for lysed cells, intact 
dead cells and viable cells.  Viable cells were counted in each sample, normalized based 
on the fluid volume analyzed by the flow cytometer and then normalized to the viability 
of a control sample.  The analysis time of a sample in the flow cytometer was used as a 
measure of the sample volume analyzed, since the flow cytometer operated at a constant 
flow rate.  A similar technique was used with fluorescent beads, as described by Guzman 
et al. (2001).  
Broadband noise detection and calculations 
A passive cavitation detection system was used to monitor cavitation and 
consisted of a custom broadband piezopolymer hydrophone (bandwidth of 1 kHz to 13 
MHz, Sonic Concepts) with an active diameter of 13 mm.  The hydrophone was placed at 
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an angle of 90º to the direction of sound propagation and approximately 7.5 cm from the 
sample position to collect only sound scattered from the sample or emitted from 
cavitation occurring within the sample.  The signal from the hydrophone was amplified 
(Sonic Concepts) and then recorded by a flexible, high-speed, high-resolution digitizer 
(NI 5911, National Instruments, Austin, TX, USA) and LabVIEW software (National 
Instruments) operating on a personal computer.  The digitizer was synced to the function 
generator that controlled the duty cycle of the ultrasound so recordings were only 
collected during the on-time of ultrasound exposure.  The data acquisition card was used 
at a collection frequency of 12.5 x 106 samples per second and 11 bit accuracy.  To 
analyze the acoustic emissions, the recorded data were processed using fast-fourier 
transform (FFT) analysis in MATLAB (MathWorks, Natlick, MA, USA) to create 
frequency spectra of the recorded sound.  Each burst of 1 ms yielded 12500 discrete 
points that were analyzed by FFT analysis, creating one frequency spectrum graph for 
every millisecond of exposure. 
To measure cavitation, a value based on the broadband noise was calculated and 
termed the cavitation dose.  A representative value of the broadband noise for each burst 
of ultrasound was determined by averaging the signal magnitude from 2.3-2.5 MHz on 
the frequency spectrum graphs.  Average broadband noise measurements were graphed 
over the total number of bursts (exposure time) of each sample and characteristic features 
of the cavitation activity, including peak broadband noise, exposure time at peak 
broadband noise and half-life of broadband noise, were measured.  The cavitation dose 
was calculated by summing the broadband noise on each frequency spectrum graph until 
the broadband noise decayed to a constant value.  At this point, the cavitation activity 
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was considered to be insignificant and the broadband noise magnitude at this level was 
subtracted from all spectra as background.  In samples where the broadband noise did not 
decrease to a constant level, i.e., samples with short exposure times, the broadband noise 
level of samples without Optison® exposed at the same pressure was subtracted as the 
background. 
Statistical Analysis 
For conditions at 1.7% v/v Optison® at 1.1 and 3.1 MHz, a minimum of three 
replicates were performed for all acoustic conditions (i.e., pressure and exposure time).  
Replicates enabled calculation of means, standard deviations and standard errors of the 
mean for all conditions.  Analysis of variance (ANOVA, α=0.05) was utilized to compare 
all parameters to determine their statistical significance in affecting molecular uptake and 
loss of viability.  To test the robustness of the correlation of bioeffects with broadband 
noise, a broader range of experimental conditions were tested without any replicates, 
including samples at 0.25% v/v and 14.3% v/ v Optison®.  The experimental and acoustic 
conditions are summarized in Table 3.1.  The strength of the correlation of bioeffects 
with broadband noise was determined by fitting the data to exponential equations and 































Table 3.1:  Replicates performed for the experimental and acoustic condition tested, 
resulting in 350 data points of bioeffects. 
 
Cell Type DU145 DU145 DU145 AoSMC
Optison Concentration 0.25 vol% 1.7 vol% 14.3 vol% 1.7 vol%
Calcein Concentraion 10 μM 10 μM 10 μM 10 μM
Frequency Pressure Exposure Time
1.1 MHz 0.5, 0.8, 1.2, 1.7, 2.0 MPa
3, 10, 30, 100, 300, 
1000, 3000 ms n=1 n=3 n=1 n=1
3.1 MHz 0.5, 0.8, 1.2, 1.7, 2.0 MPa
3, 10, 30, 100, 300, 





Ultrasonically Targeted Delivery into Vascular Cells in Ex Vivo Arteries 
Porcine carotid artery isolation and preparation 
 Porcine carotid arteries were chosen for this study because they can be delicately 
excised without tissue damage, preserving an intact and viable endothelium.  
Furthermore, carotid arteries are relatively straight vessels without much branching, 
simplifying handling and imaging of the artery.  Porcine carotid arteries were harvested 
from freshly killed female swine at a local abattoir (Holifield Farms, Convington, GA). 
Excised arteries were immediately rinsed with sterile phosphate-buffered saline (PBS, 
MediaTech, Herndon, VA) and placed in 15-ml conical tubes filled with Dulbecco's 
Modified Eagle Medium (DMEM, MediaTech) supplemented with 100 μg/ml penicillin-
streptomycin (MediaTech) and 10% (v/v) heat-inactivated fetal bovine serum (Atlanta 
Biologicals, Atlanta, GA).  Arteries were then placed on ice for approximately 1 h during 
transport to the laboratory.  Upon return to the laboratory, arteries were placed in fresh 
DMEM with 15 μM sodium nitroprusside (Sigma, St. Louis, MO) and incubated at 37oC 
for approximately 30 min while the ultrasound apparatus was prepared.  Sodium 
nitroprusside, a nitric oxide donor, was added to the media to relax the arteries, 
improving the en face images of the artery (as described below).  By testing additional 
samples without sodium nitroprusside incubation, we showed that sodium nitroprusside 
did not significantly affect the bioeffects observed after ultrasound exposure (data not 
shown).  Arteries were then cleaned of adventitial adipose and connective tissue while 




Flat artery experiments 
To prepare flat arteries for simplified exposure and analysis, the ends of the intact 
arteries were first discarded where the artery was handled with forceps, which likely 
caused tissue damage.  Arteries were then cut cross-sectionally into 1-cm length 
segments and cut lengthwise to expose the endothelial surface.  To approximate 
physiologic tension, artery segments were stretched to ~150% of their resting length 
(Chesler et al. 1998), sutured to acoutically transparent TPX® plastic disks (25 mm dia., 
Ajedium Film, Newark, DE) with the endothelium exposed (Figure 3.1), submerged in 
DMEM, and incubated at 37oC.  In select experiments, the artery endothelium was 
removed by rubbing the endothelial surface with a plastic cell scraper denuding the artery 
completely, as verified by microscopy. 
 
 
Figure 3.1:  Artery segments were sutured to TPX® plastic disks exposing the 
endothelium for flat artery experiments.  Confocal images for quantification of 




Intact artery experiments 
To better mimic the in vivo geometry and environment, intact arteries were cut 
into 2.5-cm length segments and cannulated on each end in custom-built chambers for 
ultrasound exposure.  Chambers were rectangular-shaped boxes constructed of acrylic 
plastic with metal cannulas on each end to suspend the artery lengthwise and acoustically 
transparent windows constructed of Mylar® (DuPont, Wilmington, DE) plastic to allow 
ultrasound exposure with minimal attenuation.  Physiologic stretch and pressure were 
obtained by stretching the artery by ~150% and pressurizing the artery with DMEM or 
blood to 100 mmHg.  The volume outside the artery was filled with DMEM, and then the 
chamber was incubated at 37oC. 
Ultrasound apparatus 
Ultrasound was produced using an immersible, focused, piezoceramic transducer 
(Sonic Concepts, Woodinville, WA, model no. H-101) at 1.1 MHz.  The transducer had a 
70-mm diameter, 52-mm focal length, and 1.5-mm focal width at half amplitude (-6 dB).  
Megahertz ultrasound was used in this study because frequencies in the vicinity of 1.1 
MHz have been well established in our lab and many others to nucleate microbubbles and 
cause intracellular uptake of drugs and genes (Mitragotri 2005).  Megahertz ultrasound is 
widely studied because it can be highly focused and is considered safer than lower 
frequencies, since it is less likely to spontaneously produce cavitation.  Megahertz 
ultrasound therefore requires microbubbles to nucleate cavitation and thereby adds 
another element of control by allowing one to also regulate cavitation by the 
microbubbles added to the system. 
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A sinusoidal waveform was produced by two function generators (Standford 
Research Instruments, Sunnyvale, CA, model no. DS345 and Agilent, Austin, TX, model 
no. 33120A) used in conjunction to control pulse length, frequency and peak-to-peak 
voltage.  The sinusoidal waveform was amplified by a RF broadband power amplifier 
(Electronic Navigation Industries, Rochester, NY, model no. 3100LA) before passing 
through a matching resistance network and controlling the response of the transducer.  
The transducer was housed in a polycarbonate tank (30.5 x 29 x 37 cm) 
containing approximately 26 L of deionized and distilled water at 37oC. A 5-cm thick 
acoustic absorber (SC-501 Acoustic Rubber, Sonic Concepts) was mounted opposite the 
transducer to minimize standing wave formation.  A three-axis positioning system (10 
μm resolution, Velmex, Bloomfield, NY) was mounted on top of the tank to position 
samples and a hydrophone at desired locations in the tank.  A PVDF membrane 
hydrophone (NTR Systems, Seattle, WA, model no. MHA200A) was used to measure 
spatial-peak-temporal-peak negative pressure in order to map and calibrate the acoustic 
field produced by the transducer. 
Experimental protocol 
Prior to every experiment, the desired sample placement in the acoustic field was 
found using a needle hydrophone (NTR Systems, model no. TNU001A).  This location 
was approximately 1 cm out of the ultrasound’s focus towards the transducer.  
 Prior to ultrasound exposure, a solution for each sample was prepared with 
DMEM, 4 μM TO-PRO®-1 (Invitrogen, Molecular Probes, Eugene, OR), and 1.7% v/v 
(~ 1.1 x 107 bubble/ml) Optison® (Mallinckrodt, St. Louis, MO).  TO-PRO®-1, a green 
fluorescent nucleic acid stain that is impermeable to intact cell membranes, was used as a 
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model drug and to quantify intracellular uptake into viable cells.  TO-PRO®-1 emits little 
fluorescence until it binds to nucleic acids inside cells, which facilitates analysis by 
confocal microscopy by almost eliminating background noise from extracellular TO-
PRO®-1.  In select intact artery experiments, whole porcine blood, collected from the 
abattoir, with 5 USP units/ml of heparin (Baxter, Deerfield, IL) was used in place of 
DMEM to further imitate physiologic conditions. 
 Optison® is a suspension of perfluorcarbon gas bubbles stabilized with denatured 
human albumin that is a FDA-approved ultrasound imaging contrast agent but was used 
in this study to nucleate cavitation activity (Kamaev et al. 2004).  Optison® bubbles of 
mean diameter 3-5 μm are expected to have a resonant frequency of  ~2 MHz and a peak 
negative pressure threshold for inertial cavitation of ~0.4 MPa at 1.1 MHz (Leighton 
1994).  Optison is considered unstable when exposed to air and can be difficult to keep in 
a homogenous suspension due to buoyancy of the bubbles.  Therefore, Optison was only 
added immediately before ultrasound exposure.  During long ultrasound exposure, 
intense mixing caused by cavitation activity was expected to keep the solution 
homogenous.  It is envisioned that microbubbles of the relatively high concentrations 
used in this study could be obtained in the body by local catheter release of microbubbles 
(Amabile et al. 2001)  or by targeted microbubbles (Klibanov 2006). 
 Flat arteries were placed in cylindrical sample chambers that had the ends sealed 
with acoustically transparent TPX® plastic.  Immediately before ultrasound exposure, 
sample chambers containing flat arteries were filled with a sample solution of media, 
model drug, and Optison®.  Intact arteries were filled with the sample solution to 
physiologic pressure (~100 mmHg).  Sample chambers were then placed in the desired 
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location in the ultrasound apparatus using the three-axis positioning system to orient the 
flat artery surface and the intact artery segment perpendicular to the acoustic beam. 
Ultrasound was applied to each sample at 1.1 MHz and acoustic energies of 5.0 
(0.7 MPa – 300 ms), 66 (1.4 MPa – 1000 ms), or 630 J/cm2 (2.5 MPa – 3000 ms), 
referred to as low, intermediate, and high ultrasound energy, respectively.  To avoid 
heating, ultrasound was applied in 1-ms bursts followed by 99 ms of off time, a 1% duty 
cycle.  Inertial cavitation production during ultrasound exposure was verified using a 
passive cavitation detection system (i.e., monitoring broadband noise).  Cavitation 
detection further showed that cavitation activity was sustained for many bursts equivalent 
to several hundreds of milliseconds of ultrasound exposure.  After ultrasound exposure, 
samples were immediately incubated at 37oC for 15 min to allow arteries to “recover”. 
Arteries were then rinsed with DMEM and incubated at 37oC for < 20 min until all 
samples had been exposed. 
After ultrasound exposure, intact arteries were removed from their chambers, cut 
open lengthwise and sutured to rectangular TPX® plactic slides exposing the 
endothelium.  Artery segments were then placed in DMEM with 0.07 mg/ml Hoechst 
33342 (Invitrogen) and 7 μg/ml propidium iodide (Invitrogen) for 30 min in the 
incubator.  Hoechst 33342 stains the nuclei of all cells with blue fluorescence, while 
propidium iodide only stains the nuclei of non-viable cells with red fluorescence. 
 Microscopy 
Artery segments were observed using a Zeiss LSM 510 confocal laser-scanning 
microscope or Zeiss LSM META/NLO 510 multiphoton microscope (Zeiss, Thornwood, 
NY).  Images of the endothelium and media were captured by directing a 40X 
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magnification oil objective or a 10X magnification objective at the endothelial surface of 
the artery.  To grasp the extent and pattern of the bioeffects, a larger area of the 
endothelium was captured by taking four overlapping confocal images at 10X 
magnification and arranging them as a montage.  
Quantification and statistical analysis 
Quantification of endothelial bioeffects was objectively determined by capturing 
20 images at specific locations relative to suturing holes that affixed the artery to the 
plastic disk.  Twenty images of the artery endothelium were captured in a 5 by 4 array at 
40X magnification for each sample of the flat artery experiments (Figure 3.1).  Images 
were then processed in Image-Pro® Plus (Media Cybernetics, Silver Spring, MD) to count 
all ECs (blue florescence), non-viable cells (red fluorescence), and viable cells with 
model drug uptake (green fluorescence).  Typical control samples would contain at least 
4,000 ECs.  The number of cells for each population was averaged for each energy and 
normalized to the control sample. 
Statistical analysis was performed by use of Paired Student’s t-Tests and analysis 
of variance (ANOVA) on quantified bioeffects from flat artery experiments.  Values of P 




Shear-Induced Loading of Cells with Macromolecules by Controlled 
Microfluidics 
Cell culture 
Cell culture was performed as described by Guzman et al. (2001).  In brief, human 
prostate cancer cells (DU145, American Type Culture Collection, Manassas, VA, item no. 
HTB-81) were cultured as monolayers in a humidified atmosphere of 95% air and 5% 
CO2 at 37oC in RMPI-1640 media (Cellgro, Mediatech, Herndon, VA), supplemented 
with 100 μg/ml penicillin-streptomycin (Cellgro) and 10% (v/v) heat-inactivated fetal 
bovine serum (Atlanta Biologicals, Atlanta, GA).  DU145 cells were harvested by 
trypsin/EDTA (Cellgro) digestion, washed, and resuspended in culture media. 
Cone-and-plate shearing device 
 DU145 cells were subjected to a high-magnitude, short-duration pulse of fluid 
shear stress using a custom-built, cell-shearing injury device (CSID) capable of 
delivering high magnitudes of shear stress, at rapid rates, to cell cultures (Prado et al. 
2005).  The CSID consisted of a servo motor-driven cone (0.5o) that rotates above the cell 
culture surface at controlled speeds and rates of acceleration.  Hank’s Balanced Salt 
Solution (HBSS) (Sigma, St. Louis, MO) was placed between the cone and cell plate to 
serve as shearing buffer, transferring momentum from the rotating cone to the plate of 
seeded cells and producing a uniform shear stress across the culture plate. 
 Prior to shear exposure, cells were counted and seeded (density = 1.00 – 1.25 x 
105 cells / cm2) onto customized culture plates.  Culture plates consisted of glass plates 
that were briefly flamed and subsequently coated with a poly-L-lysine solution (0.0023% 
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w/v; Sigma) for at least 12 h at 37 oC, 95% relative humidity before cell seeding. Cells 
were cultured as monolayers with culture media and in an incubator, as described above.  
Shear stress experiments were conducted by removing culture plates from the 
incubator and rinsing them with HBSS.  Cells were then incubated at 37 oC in the buffer 
containing calcein (0.34 mM, Molecular Probes, Eugene, OR) for 10 min and mounted in 
the CSID.  The cone of the CSID was lowered until its apex contacted the center of cell 
plate, and then shearing buffer (HBSS) was added through a perfusion port in order to fill 
the gap between the cone and the plate.  The applied shear stress magnitude and duration 
were 140 dynes/cm2 and 300 ms, respectively.  The rise time, which is defined to be the 
length of time for the cone to reach maximum velocity, was 20 ms.  Cells were 
immediately removed from the CSID and analyzed by flow cytometry to determine 
viability and intracellular uptake of calcein, as described below.  Cells exposed to shear 
were compared to cells in sham samples (i.e., cells treated exactly the same but not 
exposed to shear). 
Microchannel fabrication 
Sheets of polyethylene terephthalate (Mylar®, Dupont, Wilmington, DE) were 
used to make microchannels because this material is inexpensive, available in many 
different thicknesses, and easily cut using established laser-cutting techniques.  Mylar® 
sheets measuring 100 μm and 250 μm in thickness were first cut into 15-mm diameter 
disks using a CO2 laser (LS500XL, Gravograph-New Hermes, Duluth, GA).  The CO2 
laser was operated with 30% power and 10% speed in the circular pattern until the laser 
cut completely through the sheet.  Microchannels were created in each disk as a single 
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cylindrical channel, a single conical channel, or an array of conical channels by drilling 
near the center with an ultraviolet excimer laser (Resonetics Micromaster, Nashau, NH).  
As shown in Figure 3.2 A, the relatively flat energy profile of the excimer laser 
allowed nearly cylindrical microchannels to be created in the Mylar®sheets with only a 
slight taper: typically a 10 μm difference between the inlet and outlet diameter over 100 
μm of channel length (Davis et al. 2005).  The laser was operated at 60 Hz with a 248 nm 
wavelength and energy of 200 mJ per pulse.  To create a more uniform cylindrical 
profile, Mylar® disks were drilled with the excimer laser from both sides, which 
eliminated most of the taper such that inlet and outlet diameters differed by less than 5 
μm over a 100-μm channel length.  A wide range of microchannel diameters and lengths 
could be created using different sized masks for the excimer laser and the many available 
thicknesses of the Mylar® sheets, respectively.  
To create conical channels in the Mylar® disk, the excimer laser was operated in a 
trepanning mode (Davis et al. 2005), as shown in Figure 3.2 B.  During trepanning, the 
disk was moved in an overlapping circular motion allowing the excimer laser to ablate 
the Mylar® with greater intensity at the center of the circular path than at the edges, 
thereby creating a conical profile.  Various conical profiles could be created by using 
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Figure 3.1:  Microchannels were drilled in Mylar® sheets to produce (A) cylindrical 
or (B) conical microchannels as (A) a single channel or (B) as an array of channels. 
(A) displays a single cylindrical microchannel with a diameter of 50 μm, while (B) 
displays a 3 x 3 array of conical microchannel with an inlet diameter of 300 μm and 
an outlet diameter of 50 μm.  (C) A device was created to secure microchannel disks 
in place with a water-tight seal to ensure flow through microchannels and to couple 
a syringe and tubing for dispensing and collecting of cell solution, respectively. 
 
Microchannel device 
To flow cell suspensions through the microchannels, a device was created to 
securely hold the Mylar® disk in place and allow coupling to tubing and a syringe (Figure 
1C).  To secure the Mylar® disks, two flanges constructed of 1/4-in. thick 
polymethylmethacrylate (acrylic, McMaster-Carr, Atlanta, GA) were used.  Each  acrylic 
flanges had a hole drilled in the center to allow fluid flow and four holes near the edge of 
the flange for securing screws.  To prevent leakage within the flange, gaskets were cut 
from rubber gasket sheets (SBR rubber, 1/16-in thick, McMaster-Carr, Atlanta, GA) with 
an outer diameter of 15 mm and a hole was removed from the center with a diameter of 3 
mm.  Two gaskets were centered on each side of the Mylar® disk and held securely in 
place using the acrylic flanges and screws.  To couple tubing and a syringe to the flange, 
a nozzle tip connection for 1/8-in. tubing was screwed into the outlet of the flange and a 
male luer fitting screwed into the inlet of the flange. 
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Experimental protocol of microchannel exposure 
Prior to fluid flow through microchannels, samples were prepared at a cell 
concentration of 5 x 105 cells/ml.  To test the ability of this device to cause intracellular 
uptake, one of several different cell-impermeant, green-fluorescent molecules of different 
sizes was added to the cell sample: calcein (10 μM, 623 Da, Molecular Probes), FITC-
labeled dextrans (150, 500, and 2000 kDa, Sigma, St. Louis, MO), and FITC- labeled 
BSA (66 kDa, Sigma). 
A 2-ml sample solution was aliquoted into a 3-ml syringe (Becton Dickinson, 
Franklin Lakes, NJ) and any entrapped air was removed from the syringe.  The male luer 
connection on the microchannel device was then filled with additional cell solution, 
which displaced any air in the fitting upstream from the microchannel, and was connected 
to the syringe.  To accurately flow the sample through the microchannel and thereby 
expose cells to a controlled shear, a syringe pump (Genie, Kent Scientific Corp, 
Torrington, CT) was used to set the flow rate at 30, 70, or 100 ml/h.  Approximately 0.5 
ml of sample was allowed to flow through the microchannel before any sample was 
collected, and then at least 1.0 ml of sample solution was collected in a 1.5 ml 
microcentrifuge tube (Eppendorf, Brinkman, Westbury, NY).  Cells were allowed to 
“recover” for 5 min at room temperature, and then microcentrifuge tubes were incubated 
on ice until all samples had been exposed (< 2 h).   
After all samples had been exposed, 1.0 ml of sample solution was pipetted from 
each collected sample and dispensed into a new microcentrifuge tube for analysis.  Cells 
were then centrifuged (800 x g, 3 min, Eppendorf 5415C, Brinkman, Westbury, NY) and 
washed with PBS (Cellgro) three times to remove extracellular fluorescent molecules in 
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the supernatant.  The subsequent cell pellets were resuspended in a final volume of 205 
μl of PBS containing 2 μg/ml of propidium iodide (Molecular Probes), which is a 
viability marker that stains non-viable cells with red fluorescence. 
Quantification of bioeffects 
Flow cytometry was used to determine molecular uptake, i.e., fraction of cells 
containing intracellular fluorescent molecules, and loss of cell viability by detecting the 
fluorescence intensity from uptake molecules and propidium iodide, respectively, on a 
cell-by-cell basis.  A BD LSR benchtop flow cytometer (BD Biosciences, San Jose, CA) 
was used to measure the green fluorescence of cells with intracellular uptake (FITC 
fluorescence, 530/28 nm bandpass filter) and to distinguish viable from non-viable cells 
by the red fluorescence of propidium iodide (Per CP fluorescence, 670 nm longpass 
filter).  Typical analyses each included approximately 30,000 cells per sample.  Since the 
flow cytometer could not count fragmented cells, the rate of viable cells counted in each 
sample was normalized to the rate of all cells counted in a non-exposed sample.  Since 
the flow cytometer operated a constant flow rate, this method accounted for both intact 
and fragmented non-viable cells.  
Statistical analysis 
A minimum of three replicates was performed for all conditions.  Replicates 
enabled calculations of means and standard errors of the mean (SEM).  Analysis of 
variance (ANOVA, α=0.05) was utilized to compare all parameters to determine their 
statistical significance in affecting molecular uptake and loss of viability. 
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CHAPTER 4 




Using broadband noise as a measure of cavitation activity, this study determined 
the kinetics of cavitation during sonication of Optison® contrast agent and tested whether 
cellular bioeffects can be predicted by cavitation dose.  Cell suspensions were exposed to 
ultrasound at varying acoustic frequency, pressure, exposure time, Optison® 
concentration and cell type to obtain a broad range of bioeffects, i.e., intracellular uptake 
and loss of viability, as quantified by flow cytometry.  We found that cavitation activity 
measured by broadband noise increased and peaked within 20 ms and then decayed with 
a half-life of tens to hundreds of milliseconds.  Intracellular uptake and loss of viability 
correlated well with the cavitation dose determined by the time integral of broadband 
noise magnitude.  These results demonstrate that broadband noise correlates with 
bioeffects over a broad range of experimental conditions, which suggests a noninvasive 
feedback method to control ultrasound’s bioeffects in real time. 
Introduction 
Intracellular delivery of drugs, proteins and genes is often critical to the success of 
biopharmaceutical therapy, but is limited by the transport barrier imposed by the cell 
membrane (Stein and Lieb 1986).  A wide variety of techniques is therefore being studied 
to drive molecules across the cell membrane and into cells.  These include 
______________________________ 
1This work was published in Ultrasound in Medicine Biology:  Hallow DM, Mahajan AD, 
McCutchen TE, Prausnitz MR. Measurement and correlation of acoustic cavitation with cellular 
bioeffects. Ultrasound in Medicine and Biology 2006; 32 (7): 1111-1122.  
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physical approaches, such as acoustic cavitation (Mitragotri 2005), shock waves (Doukas 
and Flotte 1996) and electroporation (Gehl 2003); chemical methods, such as lipid- and 
polymer-based complexes and particles (Langer 1998); and biological means, such as 
viral vectors (Gardlik et al. 2005) and receptor targeting (Vyas et al. 2001).  Ultrasound-
enhanced delivery, a physical method temporarily to permeabilize cells using cavitation, 
has received growing attention over the past decade, because of its potential to 
noninvasively deliver drugs, DNA and other molecules into targeted cells (Ng and Liu 
2002; Unger et al. 2001). 
Ultrasound has been studied in various experimental systems ranging from cell 
suspensions to monolayers to tissues, both in vitro and in vivo, and with intracellular 
delivery into a variety of cell types, including mammalian and plant cells (Bekeredjian et 
al. 2005; Liu et al. 2005; Mitragotri 2005).  Cells have been studied using a range of 
different compounds ranging from small fluorescent molecules to macromolecules, such 
as proteins and DNA (Miller et al. 2002), to nanoparticles (Mehier-Humbert et al. 2005).  
Furthermore, a wide range of ultrasound parameters has been tested by varying acoustic 
frequency, pressure, energy, exposure time and duty cycle.   
In general, experimental systems and acoustic conditions have been designed to 
produce cavitation, which is believed to be responsible for bioeffects (Miller et al. 1996). 
The mechanism is thought to involve localized shear forces from microstreaming and 
bubble collapse that disrupt cell membrane microstructure enough to allow transport of 
molecules into the cell (Lokhandwalla and Sturtevant 2001) but not so much to injure the 
cell beyond repair (McNeil and Steinhardt 2003; Schlicher et al. 2006). 
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To advance ultrasound-enhanced delivery for medical and biological applications, 
additional research is needed to control ultrasound’s bioeffects reliably in various in vitro 
and in vivo environments.  Bioeffects can be difficult to control and reproduce, even in 
simplified in vitro systems, because cavitation activity is typically a complex milieu of 
stochastic bubble oscillations and collapses (Apfel 1997).  Different acoustic parameters, 
such as pressure, frequency and exposure time, and experimental conditions, such as 
nucleation bubble concentration and viscosity, can result in vastly different amounts and 
intensities of cavitation.   
To develop methods to predict and to control ultrasound’s bioeffects 
reproducibly, some research has focused on correlating acoustic and experimental input 
parameters with the bioeffects (Guzman et al. 2001).  For example, acoustic energy 
exposure has been shown to correlate with bioeffects over a range of pressures and 
exposure times, but fails when acoustic frequency or nucleation bubble concentration are 
changed (Guzman et al. 2003; Sundaram et al. 2003).  This failure may be explained by 
considering the mechanism of ultrasound’s effects.  Cavitation activity is believed to be 
directly responsible for bioeffects, whereas ultrasound, which is used to produce 
cavitation, is only indirectly associated with bioeffects.  We therefore expect that 
measurements of output parameters produced by cavitation should correlate with 
bioeffects better than the input parameters of ultrasound used to generate cavitation.   
Guided by this rationale, this study is designed to test the hypothesis that 
measurement of broadband noise produced by inertial cavitation correlates broadly with 
bioeffects.  This hypothesis is supported by previous studies that correlated bioeffects 
with measurements of inertial cavitation, such as sonoluminescence (Cochran and 
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Prausnitz 2001), free radical formation (Kondo et al. 1993) and frequency spectrum 
analysis (Chen et al. 2003; Daniels et al. 1995; Liu et al. 1998; Sundaram et al. 2003).  In 
this study, we measured intracellular uptake of molecules and loss of cell viability over a 
wide range of acoustic pressure, exposure time, frequency, cell type and contrast agent 
concentration.  We then sought to correlate these bioeffects with measurements of 
broadband noise, with the goal of identifying a unifying parameter that correlates with 
bioeffects over the large set of parameters tested.  Broadband noise could be measured 
during sonication to provide real-time feedback about the cavitation and bioeffects 
produced by ultrasound, which may provide a means actively to control acoustic 
bioeffects under diverse experimental conditions.  
Results 
Measurement of cavitation activity nucleated by contrast agent  
Because inertial cavitation bubble collapse is believed to be responsible for 
ultrasound’s bioeffects, our first goal was to measure this cavitation activity during 
sonication.  Cavitation was characterized by analyzing acoustic emissions from cell 
samples exposed to ultrasound.  Sound was recorded with a hydrophone and later 
analyzed by FFT analysis to extract frequency spectra. 
Figure 4.1 A and B shows representative frequency spectra collected during 
sonication of cell suspensions with Optison®.  Features of the acoustic spectra consist of a 
strong signal at the driving frequency (f, 1.1 or 3.1 MHz) as well as characteristic 
markers of cavitation, such as subharmonics (i.e., f/2), ultraharmonics (i.e., 3/2f, 2f) and 
high levels of broadband noise. Samples exposed to ultrasound without cells but with 
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Optison® exhibited similar features and magnitudes in the frequency spectra (data not 
shown).   It is generally accepted that harmonic, subharmonic and ultraharomic signals 
are produced at the onset of cavitation and typically arise from stable cavitation bubbles 
oscillating linearly and nonlinearly with the pressure transients of ultrasound (Leighton 
1994).  These features are superimposed onto a level of broadband noise that results from 
erratic oscillations and bubble collapse, primarily from inertial cavitation (Neppiras 
1980). 
We focused on broadband noise measurements as a measure of inertial cavitation 
(ASA, 2002) based on the expectation that observed bioeffects result from inertial bubble 
collapse (Miller et al. 1996).  By monitoring the broadband noise, we were attempting to 
measure the energy output in the form of sound from bubble collapses of inertial 
cavitation (ASA, 2002).  Representative broadband noise measurements were obtained 
from the frequency spectra by averaging the signal magnitude from 2.3 to 2.5 MHz, a 
sampling region absent of any harmonics at 1.1 or 3.1 MHz (Figure 4.1A and B). 
Average broadband noise levels are shown in Figure 4.2 as a function of the 
exposure time to display the dependence of cavitation activity kinetics on acoustic 
frequency (Figure 4.2A), acoustic pressure (Figure 4.2B) and Optison® concentration 
(Figure 4.2C).  The measured cavitation was found to be a transient response, increasing 
to a maximum within 20 ms of ultrasound exposure time and then decreasing to 
background values over tens to hundreds of milliseconds.  In general, the total cavitation 
activity, as measured by the time integral of broadband noise, generally increased with 





Figure 4.1:  Representative frequency spectra derived from acoustic emissions of 
cell samples exposed to (A) 1.1 MHz and (B) 3.1 MHz ultrasound.  Frequency 
spectra exhibit characteristic markers of cavitation, including subharmonics, 
ultraharmonics and high levels of broadband noise.  The sampling region to 
measure the average broadband noise was chosen between 2.3 and 2.5 MHz, absent 
of any harmonic signals.  (C) Representative graph displaying characteristic 
measurements of cavitation activity, including peak broadband noise magnitude, 
exposure time at peak broadband noise and half-life of broadband noise. 
 
We can further interpret these data by recognizing that broadband noise is 
generated by both the initial rupture of stabilized gas bubbles added as nucleation sites 
and the destruction or dissolution of secondary bubbles generated and recycled over time.  
Strong broadband noise during the first milliseconds is believed to represent the emission 
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and scattering of sound by the initially large concentration of Optison® bubbles.  In most 
cases, broadband noise increased during the first several bursts, which is believed to be 
caused by the initial collapse of Optison® bubbles and the resulting increase in secondary 
bubbles collapsing.  This characteristic increase has been previously observed by 
monitoring cavitation emissions (Chen et al. 2002).  The subsequent decrease in 
broadband noise is believed to indicate the loss of bubbles that are destroyed by inertial 
collapse or loss of stability, which reduce both sound scatter and emissions.  Eventually, 
broadband noise decreases until it remains relatively constant near background levels, the 
point where inertial cavitation activity should no longer exist or be significant to induce 
bioeffects. 
 The kinetic activity in Figure 4.2 further depends on experimental parameters.  
Specifically, the peak broadband noise depends strongly on frequency and pressure, and 
the delay time until peak broadband noise and rate of destruction also strongly depend on 
Optison® concentration.  To investigate these characteristic features further, a quantitative 
analysis of the data was performed to show characteristic features of cavitation activity as 
a function of frequency (Figure 4.3A), pressure (Figure 4.3B) and Optison® concentration 
(Figure 4.3C).  These features, shown in the representative graph Figure 4.1C, include 
peak broadband noise magnitude (interpreted as the point when the largest number of 
bubbles was collapsing inertially), the corresponding exposure time at peak broadband 
noise and the half-life of broadband noise, which is a measure of the rate of bubble 
destruction.   
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Figure 4.2:  Kinetic activity of cavitation measured by broadband noise and 
dependence on acoustic and experimental parameters.  Cavitation activity rapidly 
achieved a peak value and then decayed over time.  (A) Exposure as a function of 
frequency (1.1 and 3.1 MHz) at two different pressures (0.5 and 2.0 MPa).  Higher 
frequency yielded lower levels of cavitation activity.  (B) Exposure as a function of 
pressure (0.5 – 2.0 MPa).  Cavitation activity decreased with decreasing pressure.  
(C) Exposure as a function of Optison® concentration (0.25 – 14.3 vol%).  Increasing 
Optison® concentration increased amount and duration of cavitation activity.  
Samples contained suspensions of DU145 prostate cancer cells.  Most data represent 




Figure 4.3:  Characteristic features of cavitation activity derived from Figure 4.1 
showing the effect of (A) Acoustic frequency, (B) Pressure and (C) Optison® 
concentration on (1) peak broadband noise magnitude, (2) exposure time at peak 
broadband noise magnitude and (3) half-life of broadband noise.  Data represent the 
averages of n ≥ 12 with SEM error bars.  
 
Considering the effects of ultrasound frequency, Figure 4.3 A shows that 
increasing frequency decreased peak cavitation activity (Figure 4.3 A1; ANOVA, 
P<0.0001), but did not have a statistically significant effect on the time constants 
associated with onset and decay of cavitation (Figures 4.3 A2-A3; ANOVA, P=0.958 and 
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P=0.756, respectively).  In contrast, elevated pressures, as shown in Figure 4.3B, 
produced higher peak levels of inertial cavitation (Figure 4.3 B1; ANOVA, P<0.0001) 
that reached peak levels and decayed with similar time constants (Figures 4.3 B2-B3; 
ANOVA, P=0.895 and P=0.0566, respectively).  In Figure 4.3 C, increasing Optison® 
concentration did not affect peak cavitation levels with a coherent trend (Figure 4.3C1; 
ANOVA, P=0.0247), but did increase the delay to onset and decay of cavitation (Figures 
4.3C2-C3; ANOVA, P<0.0001 and P<0.0001, respectively).   
Dependence of bioeffects on acoustic and experimental parameters 
Having established a means to quantify inertial cavitation activity using 
broadband noise, our next objective was to quantify cellular bioeffects resulting from that 
cavitation activity.  Over the same range of ultrasound exposure conditions assessed in 
Figures 4.2 and 4.3, we measured intracellular uptake of a fluorescent marker compound 
(calcein) and measured cell viability. 
 Figures 4.4 and 4.5 display the wide range of acoustic and experimental 
conditions tested and the broad range of resulting bioeffects.  These bioeffects varied 
from mild conditions that caused low levels of uptake or almost no cell death, to 
moderate conditions that caused uptake into as many as one-third of cells and some cell 
death, to strong conditions that killed almost all cells.  In each figure, the total height of 
each bar represents the percent of cells remaining viable after sonication, which is 
subdivided into a black bar, representing the percent of viable cells with uptake (the 
typically desirable population), and a grey bar, representing the percent viable cells 
without uptake (the apparently unaffected population).  All samples were normalized to 
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the control sample (i.e., “sham” sonication) taken to represent 100% viability and 0% 
uptake. 
 
Figure 4.4:  Cell viability and intracellular uptake populations following sonication 
over a range of pressures, exposure times and Optison® concentrations.  The total 
height of each bar represents the fraction of cells remaining viable, the size of the 
black stripe represents the fraction of cells with significant levels of intracellular 
uptake and the size of the grey stripe represents the fraction of cells that were 
apparently unaffected.  Ultrasound was applied at 1.1 MHz to samples containing a 
suspension of DU145 prostate cancer cells and Optison® at concentrations of (A) 
0.25 vol%,  (B) 1.7 vol% and (C) 14.3 vol%.  Data in (B) represent the averages of n 
= 3 replicates with SEM shown, while data in (A) and (C) represent n = 1. 
 
Figure 4.4 displays the effect of changing the concentration of Optison®, i.e., 
nucleation sites for cavitation, over a range of pressures and exposure times.  The effects 
of frequency and cell type are shown in Figure 4.5, where two different cell types, aortic 
smooth muscle cells and prostate cancer cells, were sonicated at two different 
frequencies, 1.1 and 3.1 MHz, over the same range of pressures and exposure times.   
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In Figures 4.4 and 4.5, independently increasing pressure or exposure time 
increased the fraction of cells affected by cavitation activity by increasing both the 
fraction of cells with uptake and the fraction of cells killed (ANOVA, P<0.0001).  The 
interaction of pressure and exposure time also had a statistically synergistic effect 
(ANOVA, P<0.0001).  Increasing Optison® concentration (Figure 4.4) and decreasing 
frequency (Figure 4.5) also increased bioeffects, by increasing uptake and cell death 
(ANOVA, P < 0.001).  In general, greater uptake and lesser cell death were seen in 
DU145 cells than in AoSMC cells (Figure 4.5).  These finding are generally consistent 
with previous work (Guzman et al. 2001).  They are also consistent with a cavitation-
based mechanism for bioeffects; cavitation activity is known to show the same qualitative 
dependence on experimental conditions, where increased pressure, exposure time and 
Optison® concentration, as well as decreased frequency, all increase cavitation activity 
(Leighton 1994).  A quantitative analysis of this relationship follows immediately below.  
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Figure 4.5:  Cell viability and intracellular uptake populations following sonication 
over a range of pressures, exposure times, frequencies and cell types.  The total 
height of each bar represents the fraction of cells remaining viable, the size of the 
black stripe represents the fraction of cells with significant levels of intracellular 
uptake and the size of the grey stripe represents the fraction of cells that were 
apparently unaffected.  Ultrasound was applied at (A,C) 1.1 MHz and (B,D) 3.1 
MHz to a suspension of (A,B) DU145 prostate cancer cells and (C,D) AoSMC at an 
Optison® concentration of 1.7 vol%.  Data in (A) and (B) represent the averages of n 
= 3 replicates with SEM shown, while data in (C) and (D) represent n = 1. 
 
Correlation of bioeffects with measurement of cavitation activity   
 Having collected paired data sets of cavitation activity and bioeffects caused by 
the same ultrasound exposures, we could now test the hypothesis that broadband noise 
provides a single measurement that broadly correlates with acoustic bioeffects.  This 
hypothesis is guided by the expectation that measuring an experimental output parameter 
generated by the cavitation mechanistically responsible for bioeffects should provide 
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better correlation than experimental input parameters, such as acoustic conditions and 
Optison® concentration, which are only indirectly related to the mechanistic driving 
force.  
 To test this hypothesis, Figures 4.6A–C contain all of the 350 bioeffects data 
points shown in Figures 4.4 and 4.5 involving different pressures, exposure times, 
frequencies, Optison® concentrations and cell types plotted versus acoustic energy 
exposure, i.e., an experimental input parameter.  Previous studies have shown that 
intracellular uptake and cell viability correlate with energy exposure over a broad range 
of acoustic conditions, since the energy of cavitation is related to the total acoustic energy 
input (Leighton 1994).  However, energy exposure correlated poorly with our data set (R2 
< 0.1), probably because the single parameter of energy exposure is not sufficient to 
account for the effects of ultrasound frequency or Optison® concentration.   
 Instead of relying on an acoustic input parameter, Figures 4.6D–F show acoustic 
bioeffects as a function of a cavitation output parameter based on broadband noise 
measurement.  The x-axis represents the integral of broadband noise pressure over time 
determined from graphs such as those shown in Figure 4.2.  Measurements of the 
“cavitation dose” in this manner has previously been shown to correlate with hemolysis 
(Chen et al. 2003; Everbach et al. 1997; Liu et al. 1998) and with molecular uptake and 
viability (Sundaram et al. 2003).   
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Figure 4.6: Correlation between (A,B,C) Acoustic energy and (D,E,F) Broadband 
noise measurement with (A,D) Percent viable cells, (B,E) Percent of cells with 
uptake and (C,F) Percent of viable cells with uptake from data shown in Figures 4.4 
and 4.5.  These bioeffects correlated poorly with acoustic energy input, but 
correlated better with cavitation dose based on broadband noise.  Generally, 
increasing cavitation dose decreased viability and increased uptake into viable cells.  
Data represents experimental conditions of DU145 – 1.1 MHz – 0.25 vol% Optison 
(open square), DU145 – 1.1 MHz – 1.7 vol% Optison (open diamond), DU145 – 1.1 
MHz – 14.3 vol% Optison (open triangle), DU145 – 3.1 MHz – 1.7 vol% Optison 
(open circle), AosMC – 1.1 MHz – 1.7 vol% Optison (closed triangle), AoSMC – 3.1 




In Figure 4.6D, cell viability correlated with the cavitation dose (R2 = 0.49), 
despite some scatter, and generally decreased with increasing cavitation dose above a 
threshold value.  In Figure 4.6E, the percent cells with uptake also generally correlated 
with the cavitation dose (R2 = 0.2) and generally increased with increasing cavitation 
dose, except at very large cavitation doses, where gains in uptake were outweighed by 
losses in cell viability.  Unlike Figure 4.6E, that examines cellular uptake as a function of 
all cells initially present in the sample, Figure 4.6F considers cellular uptake among only 
those cells remaining viable after sonication.  This uptake population also generally 
correlated with the cavitation dose (R2 = 0.23) and increased with increasing cavitation 
dose.  These results demonstrate that, unlike measuring acoustic input parameters that are 
indirectly associated with the cavitation mechanism, directly monitoring broadband noise 
signals generated by inertial cavitation activity can be used to correlate with cavitation-
dependent bioeffects over a broad range of acoustic and experimental parameters.   
To serve as concise mathematical representations of these correlations with 
cavitation dose, the data in Figures 4.6D–F can be summarized according to the 
following empirical expressions generated by least-squares regression: 
 
 V = e-203•BN, (4.1) 
 U = V – e-437•BN,   (4.2) 
and  
 U/V = (1 – e-234•BN). (4.3) 
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In these expressions, V is the viability as a percentage of the initial cells present, U is the 
uptake as a percentage of initial cells present and BN is the broadband noise 
measurement based on the integral of the average broadband noise over the exposure 
time.  Equations 4.1 and 4.2 were independently fitted to the data shown in Figure 4.6D 
and Figure 4.6E, respectively.  Equation 4.3 is the quotient of Equations 4.1 and 4.2.  The 
form of these equations was suggested by the results of Sundaram et al. (2003), who 
proposed a “single bubble interaction model” that predicts the uptake and viability based 
on the distribution of cells within a certain distance from a cavitating bubble.  We 
therefore expected broadband noise, a measure of the number of cavitation events, also to 
fit the uptake and viability data by these exponential forms. 
Discussion 
 In this study, the kinetic activity of inertial cavitation nucleated by Optison® was 
quantified by measuring broadband noise emissions produced from bubble oscillation and 
collapse.  Furthermore, the dependence of cavitation activity on a number of different 
acoustic and experimental parameters was determined by varying the acoustic pressure, 
exposure time, frequency, Optison® concentration and cell type.  However, the most 
significant result of this work was the correlation between inertial cavitation activity and 
cellular bioeffects.  The inertial cavitation dose, as measured by integrating the average 
broadband noise over the exposure time, correlated over a broad range of parameters with 





This correlation suggests possible laboratory and clinical applications in 
ultrasound-enhanced delivery of drugs and genes into cells.  As proposed and 
demonstrated previously, ultrasound can be used to drive drugs, proteins, DNA and other 
compounds into cells both in vitro and in vivo (Bekeredjian et al. 2005).  However, it is 
not always clear which ultrasound conditions are optimal, due to the unpredictable nature 
of stochastic cavitation.  Rather than trying to estimate the acoustic conditions that lead to 
optimal cavitation, directly measuring the cavitation dose using broadband noise could 
provide a facile means to determine the resulting bioeffects and thereby to operate at 
optimal ultrasound conditions using a noninvasive, real-time feedback measurement of 
cavitation activity.  For example, cavitation produced by targeted ultrasound in the body 
could be monitored by noninvasively recording emissions due to inertial bubble collapses 
and processed to yield a measure of the cavitation dose in real time.  This measurement 
would allow the device or its clinical operator to end ultrasound exposure when the 
cavitation dose reached a predetermined optimal level to achieve the desired bioeffect.   
The bioeffects observed as a function of cavitation dose can be classified into two 
overall regions: (i) low cavitation doses produce some uptake and retain high viabilities 
and (ii) high cavitation doses kill many cells, but produce high levels of uptake among 
those cells remaining viable.  Different applications may prefer one of these regions over 
the other.  For example, most drug or gene delivery applications would favor the first 
region to deliver compounds into cells while retaining high viability.  In contrast, 
applications like chemotherapy, where the goal is to destroy cancerous cells at a tumor 
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site, might prefer the second region to elicit extensive cell death with large amounts of 
drug delivery to destroy the remaining viable cells with the chemotherapeutic agent.   
This technique passively to detect cavitation by recording acoustic emissions is 
attractive because it can be used noninvasively, and it also provides a direct measure of 
inertial cavitation activity.  Previous research has shown that correlations of bioeffects 
exist with sonoluminesnce (Cochran and Prausnitz 2001) and free radical activity (Kondo 
et al. 1993), which are other measures of inertial cavitation; however, they are less 
attractive because they would require more invasive and complicated systems to measure 
inertial cavitation inside the body.  Others have shown that input parameters such as 
acoustic energy can correlate with bioeffects (Guzman et al. 2001; Miller and Dou 2004; 
Sundaram et al. 2003).  However, input parameters of ultrasound are indirect and 
incomplete measures of cavitation activity and, therefore, correlations with bioeffects 
break down outside of limited ranges of applicability (e.g., Figure 4.6).  We therefore 
believe that measuring cavitation activity with sound emissions, specifically broadband 
noise, is the most promising scenario to measure cavitation dose for correlation with 
bioeffects over a broad range of acoustic and experimental parameters. 
Kinetic activity of cavitation 
This study also presented data describing the kinetic activity of cavitation and its 
dependence on acoustic pressure, frequency and Optison® concentration.  Guided by 
these observations, we hypothesize that two factors principally control the kinetic activity 
of inertial cavitation in our system and hence the measured broadband noise: these are (1) 
the initial number of bubbles capable of undergoing inertial cavitation (i.e., bubbles 
within the size range for inertial cavitation, which depends primarily on acoustic pressure 
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and frequency) and (2) the rate of destruction of bubbles by inertial cavitation, which 
depends on the volume of the sample exposed to a pressure above the pressure threshold 
for inertial cavitation.   
In our experimental system, the cell sample is exposed to a non-uniform acoustic 
field.  Perpendicular to the ultrasound beam, we have measured at the site of the sample 
chamber the pressure profile to have a half-amplitude (-6 dB) width of approximately 
10.4 mm and 2.4 mm for 1.1 and 3.1 MHz, respectively.  In the direction of the 
ultrasound beam, acoustic scattering by high concentrations of Optison® can cause 
significant attenuation, which can approach 100% during the initial bursts of ultrasound 
(data not shown).  Given these non-uniformities, only a fraction of the sample volume is 
exposed to a pressure above the threshold for inertial cavitation.  This size of this 
“cavitation zone” is expected to depend primarily on ultrasound pressure, frequency and 
Optison® concentration.   
The preceding analysis is consistent with the observed timescales of cavitation 
activity shown in Figures 4.2 and 4.3, where broadband noise decays with time constants 
of 10’s of milliseconds of “on” time, which corresponds to 1000’s of milliseconds of total 
experimental time (given a 1% duty cycle).  In contrast, previous studies show that 
uniform ultrasound exposure at high pressure (e.g, 2 MPa) should lead to inertial bubble 
collapse within microseconds (Chen et al. 2002; Leighton 1994).  The fact that bubble 
destruction occurred in our system orders of magnitude slower than predicted for a 
uniform ultrasound exposure suggests that bubbles circulate in our sample and collapse in 
only regions with high ultrasonic pressures.   
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Guided by this analysis, we believe we can explain the trends observed in Figure 
4.3.  Increasing acoustic frequency should decrease the ultrasound beam width and 
decrease the initial number of bubbles available for inertial cavitation by increasing the 
pressure threshold for inertial cavitation.  Therefore, we expect increasing frequency to 
decrease the size of the cavitation zone and thereby lower levels of peak broadband noise, 
as seen in Figure 4.3A1.  In contrast, elevated pressure should increase the initial number 
of bubbles for inertial cavitation by exceeding the pressure threshold for a greater number 
of bubbles and thereby enlarge the cavitation zone.  Thus, elevated pressure should 
increase peak broadband noise levels, as seen in Figure 4.3B1.  Finally, increasing 
Optison® concentration increases the initial number of Optison® bubbles available for 
inertial cavitation but decreases the size of the cavitation zone due to increased 
attenuation.  Therefore, we expect a lower rate of bubble destruction, which leads to 
longer times to reach the peak and half-life of cavitation, as seen in Figures 4.3C2-3. 
Dependence of bioeffects on acoustic parameters 
Another notable observation from this study was the dependence of bioeffects on 
acoustic pressure, exposure time, frequency and Optison® concentration.  It was observed 
that bioffects generally increased in uptake and decreased in viablity with increasing 
pressure, increasing exposure time, increasing Optison® concentration and decreasing 
frequency.  Furthermore, a significant synergistic effect was observed between pressure 
and exposure time.  These trends are in agreement with previous research observations 
(Guzman et al. 2001).  Taking in account the significant correlation of broadband noise 
with bioeffects and the dependence of bioeffects on these experimental parameters, these 
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results support an inertial cavitation-based mechanism, as previously proposed (Miller et 
al. 1996). 
 In conclusion, the results of this work demonstrate the potential of passively 
detecting acoustic emissions to measure cavitation activity, specifically using broadband 
noise measurements from acoustic frequency spectra.  Furthermore, the cavitation dose 
based on broadband noise measurements was shown to correlate with intracellular uptake 
and loss of viability, which suggests a unifying parameter to correlate with bioeffects.  
Using acoustic spectral analysis of cavitation activity for real-time feedback about 
bioeffects may be useful for future experimental and clinical work in ultrasound-
enhanced drug delivery applications. 
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CHAPTER 5 




 This study tested the hypothesis that ultrasound can target intracellular uptake of 
drugs into vascular endothelial cells (ECs) at low to intermediate energy and into smooth 
muscle cells (SMCs) at high energy. Ultrasound-enhanced delivery has been shown to 
enhance and target intracellular drug and gene delivery in the vasculature to treat 
cardiovascular disease, but quantitative studies of the delivery process are lacking.  
Viable ex vivo porcine carotid arteries were placed in a solution containing a model drug, 
TO-PRO®-1, and Optison® microbubbles. Arteries were exposed to ultrasound at 1.1 
MHz and acoustic energies of 5.0, 66, or 630 J/cm2. Using confocal microscopy and 
fluorescent labeling of cells, the artery endothelium and media were imaged to determine 
the localization and to quantify intracellular uptake and cell death.  At low to 
intermediate ultrasound energy, ultrasound was shown to target intracellular delivery into 
viable cells that represented 9 – 24% of exposed ECs. These conditions also typically 
caused 7 - 25% EC death. At high energy, intracellular delivery was targeted to SMCs, 
which was associated with denuding or death of proximal ECs. Significant intracellular 
uptake of molecules can be targeted into ECs and SMCs by ultrasound-enhanced delivery 
suggesting possible applications for treatment of cardivascular diseases and dysfunctions. 
Introduction 
Cardiovascular disease is one of the leading causes of death worldwide, resulting 
in nearly 17 million deaths annually (Smith et al. 2004).  Targeted drug and gene delivery 
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to vascular endothelial cells (ECs) and smooth muscle cells (SMCs) has increasingly 
become a focus for treating cardiovascular diseases and dysfunctions, such as coronary 
artery disease, hypercholesterolemia, hypertension, and restenosis, because of the pivotal 
role of these cells in controlling and maintaining vascular functions (Cines et al. 1998; 
Cooke 2000; Melo et al. 2004).  In addition, targeted drug and gene delivery to the 
endothelium is being used to treat cancerous tumors by anti-vascular therapy (Tozer et al. 
2005) and myocardial and peripheral ischemia by promoting angiogenesis (Malecki et al. 
2005).  Many drug and gene delivery systems are being developed to increase targeting to 
vascular cells, such as drug-eluting stents (Saia et al. 2005), catheter-based systems 
(Sharif et al. 2004), viral vectors (Baker et al. 2005; Quarck and Holvoet 2004), and 
targeted liposomes (Niidome and Huang 2002) and microbubbles (Kipshidze et al. 2005). 
However, most current techniques lack either the effectiveness or specificity to 
adequately treat these disorders while safely administering the therapeutic and avoiding 
toxic systemic effects or require significantly invasive intervention.  A safe, effective, 
and non-invasive method to target delivery of drugs or genes to the specific disease site 
in the vasculature would greatly benefit cardiovascular treatments.  
A novel approach to targeting drug and gene administration is the method of 
ultrasound-enhanced delivery (Unger et al. 2001).  Ultrasound-enhanced delivery often 
exploits cavitation bubble activity, a secondary effect of ultrasound, which can be 
produced by pressure oscillations of ultrasound (Mitragotri 2005).  Furthermore, 
ultrasound pressures above a certain threshold can cause oscillating bubbles to undergo 
violent collapse known as inertial cavitation (Leighton 1994).  Inertial cavitation is 
believed to cause transient disruptions in cell membranes, enabling transport of 
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extracellular molecules (e.g., drugs or genes) into viable cells (Schlicher et al. 2006; 
Sundaram et al. 2003).  Cavitation-mediated cellular disruptions can allow uptake of 
small molecules, macromolecules (e.g., proteins), and genetic material (e.g., plasmid 
DNA or siRNA).  Furthermore, ultrasound-enhanced delivery has been studied in a 
variety of in vitro and in vivo scenarios and has demonstrated promising therapeutic 
results after intracellular uptake of drugs and gene expression (Bekeredjian et al. 2005; 
Mitragotri 2005).  Most importantly, ultrasound can be focused in the body by non-
invasive extracorporeal targeted ultrasound (Huber et al. 2003) or by minimally invasive 
catheter-based transducers (Amabile et al. 2001).  Greater efficacy and reduced side 
effects could be realized by this targeted therapy. 
The vascular endothelium is an attractive target for ultrasound-enhanced delivery 
because cavitation can be readily produced in the vasculature, which currently occurs to a 
mild extent during diagnostic imaging (Correas et al. 2001).  Moreover, cavitation is 
expected to have limited effects beyond cell layers directly experiencing cavitation 
activity, and the endothelium is the first point of contact to cavitation activity (Hwang et 
al. 2005).  A number of researchers are currently studying ultrasound-enhanced gene 
therapy for cardiovascular disorders in order to control intimal hyperplasia, restore 
vascular function, or promote angiogenesis (Bekeredjian et al. 2005).  These studies have 
shown expression of reporter plasmids as well as plasmids with a therapeutic purpose. 
Clinical potential of this method has been shown by causing protein expression by 
plasmid DNA (Taniyama et al. 2002) or blocking specific proteins by oligonucleotides 
(Hashiya et al. 2004). 
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A recognized limitation of ultrasound-enhanced delivery is the need for more 
cells with drug uptake or gene expression (Bekeredjian et al. 2005).  Many studies have 
demonstrated gene transfection and tissue response in ex vivo and in vivo systems, 
however, few studies have been directed at quantifying the intracellular uptake of 
molecules and imaging bioeffects (i.e., intracellular uptake and loss of viability) caused 
by ultrasound-enhanced delivery in viable tissue (Mitragotri 2005; Mukherjee et al. 
2000).  It is important to know the uptake efficiency at different ultrasound energies in 
order to design and apply this technique for drug or gene delivery applications.  In this 
study, we sought to determine whether ultrasound-enhanced delivery of a model drug can 
be targeted into ECs and SMCs in ex vivo arteries.  This work represents the first known 
in-depth study to quantify and image the intracellular uptake of molecules and loss of 
viability to vascular cells by ultrasound-enhanced delivery.  We hypothesize that 
ultrasound can target intracellular uptake of drugs into the vascular endothelium at low to 
intermediate energy and into SMCs at high energy.  To assess this hypothesis, our goals 
in this study were to image the localization of (i) intracellular uptake of a model drug and 
(ii) loss of viability to vascular cells and (iii) to specifically quantify endothelial 
bioeffects in the targeted region.  
Results 
Endothelial bioeffects 
To test the hypothesis that ultrasound-mediated cavitation can cause intracellular 
uptake into ECs, we exposed ex vivo arterial segments to ultrasound at three different 
acoustic energies - termed low, intermediate, and high - and compared these tissues to 
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control artery segments without ultrasound exposure (i.e., sham exposure).  Figure 5.1 
displays representative en face images of the endothelium of a control tissue and a tissue 
exposed to ultrasound at the intermediate energy.  ECs are recognized by their rounded 
nuclei morphology and orientation parallel to the direction of blood flow.  
Figure 5.1A1-A2 displays the endothelium of a representative control sample.  
The control artery appears to have a complete endothelium with high viability, as 
indicated by the continuum of ECs stained with blue fluorescent Hoechst 33342 (Figure 
5.1A1) and few ECs stained with red fluorescent propidium iodide (Figure 5.1A2).  None 
of the viable ECs appears to have green fluorescent TOPRO-1 staining, verifying that 
TOPRO-1 was membrane impermeable.  These images indicate that arteries were isolated 
and handled in a manner that retained an intact endothelium and sustained the viability of 
the artery over the course of the experiment.  
We next investigated if ultrasound caused intracellular uptake in the endothelium.  
Figure 5.1B1-B2 displays the endothelium of a representative artery exposed to 
ultrasound at intermediate energy.  Fluorescently green stained ECs observed in the 
exposed sample (Figure 5.1B2) clearly indicate intracellular uptake of the model drug, 
TO-PRO®-1.  Thus, we conclude that ultrasound exposure significantly increased 
intracellular uptake into ECs. 
 We also observed that intracellular uptake appeared in a pattern of discreet 
regions or “patches” of fluorescently green nuclei on the surface of the artery (Figure 
5.1B2).  This localized pattern of intracellular uptake was regularly seen in tissues 
exposed to ultrasound.  We expect these regions of uptake can be explained by 
considering the cavitation-mediated mechanism causing bioeffects.  It is commonly 
 69
believed that bioeffects observed by this technique are due to discreet cavitation events 
and are heterogeneous within a sample due to the stochastic nature of cavitation.  Similar 
patterns of discreet regions of bioeffects have been observed in in vitro monolayers of 
cells exposed to ultrasound-mediated cavitation and attributed to individual cavitation 
events occurring near the surface of the monolayer (Brayman et al. 1999; Ohl and 
Wolfrum 2003).  We therefore hypothesize that intracellular uptake is caused by many 
individual cavitation events occurring near the surface of the artery and creates the 
observed scattered patches of intracellular uptake in the targeted region of the artery.  
 
 
Figure 5.1: Confocal microscopy 2x2 image montages (10X magnification) 
displaying the localization of intracellular uptake enhanced by ultrasound.  Images 
depict the endothelium of (A) a control sample and (B) a sample exposed to 
intermediate ultrasound energy.  EC nuclei were labeled with Hoechst 33342 (blue) 
to stain all cells, propidium iodide (red) to stain dead cells, and TO-PRO®-1 (green) 
to indicate intracellular uptake.  (A2) and (B2) are shown without blue fluorescence 
to more clearly view intracellular uptake and cell death. 
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In addition to intracellular uptake, we also sought to assess the extent to which 
ultrasound exposure caused loss of cell viability.  In Figure 5.1B2, a decrease in viability 
of the exposed sample was observed, as shown by an increase in the number of 
fluorescently red nuclei compared to the control sample (Figure 5.1A2).  This indicates 
ultrasound exposure can cause EC death. 
Guided by the general findings in Figure 5.1, we wanted to assess endothelial 
bioeffects of intracellular uptake and loss of viability in greater detail at different 
ultrasound energies.  In Figure 5.2, representative confocal images of control samples and 
samples exposed at low, intermediate, and high ultrasound energies are shown at two 
different magnifications.  The extent of bioeffects appears to sharply increase with 
increasing ultrasound energy.  The bioeffects ranged from (i) little intracellular uptake or 
cell death at the lowest energy (Figure 5.2C-D) to (ii) widespread intracellular uptake and 
reduced viabilities at the intermediate energy (Figure 5.2E-F) to (iii) widespread 
denuding of the endothelium and cell death at the highest ultrasound energy (Figure 
5.2G-H).  In Figure 5.2G1-H1, denuding of the endothelium is recognized by the lack of 
ECs and, instead, the characteristic image of the internal elastic lamina, which is highly 
autofluorescent in the blue and green channels. 
Quantification of endothelial bioeffects 
 We next wanted to quantify the extent of intracellular uptake, loss of viability and 
denuding present after different ultrasound exposures.  We used multiple en face images 
at 40X magnification (e.g., Figures 5.2B, D, F, and H) of each sample for analysis using 
image processing software to quantify the number of ECs that were (i) viable, (ii) viable 
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Figure 5.2: Confocal microscopy images of the artery surface at 10X (A, C, E, G) 
and 40X magnification (B, D, G, H) showing the range of bioeffects at different 
ultrasound energies.  Images depict (A-B) a control sample and samples exposed to 
ultrasound at (C-D) low, (E-F) intermediate, and (G-H) high energies.  Figures A2-
H2 are shown without blue fluorescence to more clearly view intracellular uptake 
and cell death. 
 
Figure 5.3 displays the percentage of cells in each of these four populations at 
low, intermediate, and high acoustic energy.  The number of viable cells with 
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intracellular uptake increased with increasing energy from the control (0% of cells) to 
low energy (9% of cells) to intermediate energy (24% of cells) (ANOVA, P < 0.002).  
The number of cells with intracellular uptake at the highest acoustic energy (8% of cells) 
decreased due to substantial loss in viability. 
Figure 5.3 further indicates that the total number of cells present on the artery 
surface and the number of viable ECs decreased with increasing acoustic energy 
(ANOVA, P < 0.001 and P < 0.001, respectively).  The difference in the total number of 
ECs compared to the control indicated the amount of denuding was only statistically 
significant at the highest acoustic energy (~67% of cells were removed, P<0.001).  The 
number of viable ECs was only significantly different when comparing the high acoustic 
energy (~25% of cells remained viable) to the control (P<0.004) and comparing the 
intermediate energy (~82%) to the control (P < 0.03).  The viability at the low energy 




Figure 5.3: Quantification of endothelial bioeffects following ultrasound exposure.  
Data represent the averages of n ≥ 5 replicates with SEM shown. 
 
 
Considering drug delivery applications, these results suggest that low proportions 
of intracellular uptake with insignificant loss in viability can be obtained at low energies, 
whereas a higher proportion of intracellular uptake with some loss of viability can be 
achieved at intermediate energy.  Finally, if a large loss of viability and significant 
denuding is tolerable (or desired), intracellular uptake can be achieved among remaining 
viable cells by applying high ultrasound energies. 
Medial bioeffects 
Having observed and quantified endothelial bioeffects caused by ultrasound-
mediated cavitation, we next determined if cavitation had any effects deeper into arterial 
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tissue to the SMCs present in the medial layer.  In some drug delivery applications, it 
may be preferable to induce intracellular uptake to the underlying SMCs, such as to 
inhibit SMC proliferation.  
By changing the focus depth of the confocal microscope, it was possible to 
optically slice the artery and capture images deeper in the tissue to approximately 40 μm 
below the endothelial surface.  In Figure 5.4A, the surface of an artery exposed to the 
highest acoustic energy was captured.  Extensive denuding of the artery was evident, 
based on the lack of ECs and the exposure of the internal elastic lamina.  Images captured 
deeper in the tissue, as shown in Figures 5.4B-C, display SMCs that are recognized by 
their long and slender nuclei and orientation perpendicular to the direction of original 
blood flow.  As indicated by propidium iodide and TO-PRO®-1 staining, SMCs in 
Figures 5.4B-C exhibited intracellular uptake, as well as loss of viability.  In tissues 
exposed at lower acoustic energies, the medial layer did not show intracellular uptake or 
loss of viability (data not shown).   
To determine if the presence of endothelial cells was a barrier to cavitation effects 
to smooth muscle cells, we pre-denuded arteries by rubbing the endothelial surface with a 
cell scraper.  Confocal images from these studies (data not shown), indicated that SMC 
bioeffects (i.e., intracellular uptake and loss of viability) were small at low to 
intermediate energy and widespread at high energy, similar to Figure 5.4.  This result 
suggests that the internal elastic lamina serves as the main barrier to cavitation, and high 




Figure 5.4: Confocal microscopy images at multiple depths in the artery displaying 
bioeffects to medial SMCs.  Images were captured at (A) the artery surface and (B) 
13 μm and (C) 21 μm below the artery surface. 
 
Overall these results demonstrate that bioeffects be can directed to SMCs in the 
medial layer of the artery; however, we expect that effects are limited to the superficial 
layers of the media considering the cavitation-mediated mechanism, which is expected to 
have limited depth penetration (Hwang et al. 2005).  This treatment of SMCs may be 
applicable in cases where denuding of the artery is tolerable or has already occurred due 
to some pretreatment, such as percutaneous coronary interventions. 
Intact arteries 
 Lastly, we wanted to determine the role of physiological conditions such as 
geometry, pressure, tension, or presence of blood (a higher viscosity fluid) on bioeffects 
induced by ultrasound exposure.  To better mimic physiologic geometry and conditions, 
intact arteries were stretched and pressurized to approximately physiologic tension and 
pressure during exposure to ultrasound at the intermediate and high acoustic energies.  
The arteries were also filled with DMEM or whole porcine blood containing Optison® 
and TOPRO-1.  
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Figure 5.5A-B display representative confocal microcopy images of an intact 
artery filled with DMEM and exposed at the intermediate and high acoustic energies.  
Similarly, Fig 5.5C-D display representative confocal microcopy images of the 
endothelium of an intact artery that was filled with whole blood and exposed to 
ultrasound at intermediate and high acoustic energies.  Intact arteries filled with either 
DMEM or whole blood and exposed at either energy displayed similar bioeffects to the 
results found in the flat artery experiments (Figure 5.1) and, therefore, show that the 
geometry and presence of blood in a pressurized and stretched vessel did not significantly 
influence ultrasound exposure to cause bioeffects.  These results also suggest that the 
bioeffects observed may be relevant for realistic drug delivery scenarios. 
 
Figure 5.5: Confocal microscopy images of endothelium displaying bioeffects 
mediated by ultrasound exposure to intact arteries at near physiologic conditions. 
Ultrasound was applied at (A, C) intermediate and (B, D) high energy while the 




Previous studies utilizing ultrasound-enhanced gene therapy have shown 
promising results of positive gene transfection in ex vivo (Teupe et al. 2002) and in vivo 
(Taniyama et al. 2002) cardiovascular tissues.  However, few studies have shown 
intracellular uptake of small molecules or macromolecules (e.g., proteins) for drug 
delivery applications in ex vivo or in vivo cardiovascular tissues (Bekeredjian et al. 2005; 
Mitragotri 2005).  Moreover, there is a lack of knowledge on the efficiency of this 
technique in terms of the number of cells affected and the relevant populations.  In this 
study, viable ex vivo porcine carotid arteries were exposed to ultrasound and 
demonstrated the ability of this method to cause intracellular uptake of small molecules 
into ECs and SMCs.  Furthermore, quantitative data showed the approximate energies 
that are relevant for drug delivery applications.   
Many cardiovascular diseases and dysfunctions would benefit from a targeted 
means to deliver drugs or genes to the endothelium (Melo et al. 2004).  Quantitative 
results (Figure 5.3) suggest that low to intermediate ultrasound energies would be 
appropriate for drug or gene delivery applications to cause intracellular uptake or 
possibly transfect a large number of cells without a large loss of viability.  Extensive cell 
death could be a drawback for drug delivery applications, since endothelial injury in the 
form of death or denudation could initiate an inflammation response or even thrombosis 
(Davis et al. 2003).  Intracellular uptake results suggest that potential applications might 
be limited to drug or gene delivery to a minority of the cell population, yet some gene 
delivery applications may not require a high transfection efficiency if the expressed 
protein is excreted and has a local effect.  To cause intracellular uptake to the majority of 
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the endothelium, repeated applications of ultrasound or other optimization approaches 
may facilitate higher uptake percentages without a harmful loss of viability.  
Cardiovascular diseases that could benefit from this method of targeted delivery include 
diseased sites such as vulnerable atherosclerotic plaques and ischemic heart or peripheral 
tissue.  Intracellular therapeutic targets such as NADPH oxidases or gene expression of 
eNOS in the endothelium could help control neointimal formation and restore vascular 
function (Melo et al. 2004; Ray and Shah 2005).  Promoting angiogenesis by intracellular 
delivery or gene expression agents such as VEGF or FGF in the endothelium could also 
benefit ischemic injuries in the myocardium or peripheral vasculature (Quarck and 
Holvoet 2004).  
In other cardiovascular diseases, drug or gene delivery to SMCs may be desired, 
especially to control SMC proliferation (Quarck and Holvoet 2004).  We found that 
ultrasound exposure could also cause medial bioeffects, which were only observed at 
high ultrasound energies.  Results suggest that cavitation is obstructed by the internal 
elastic lamina and limited to superficial cell layers.  Intracellular uptake to SMCs might 
be used in applications where denuding and loss of viability is acceptable or has already 
occurred, such as treatment for restenosis post-angioplasty.  In this potential application, 
extensive denuding and injury to the endothelium typically occurs from balloon inflation 
during percutaneous coronary interventions (Davis et al. 2003).  At this point, it may be 
advantageous to use ultrasound-enhanced cavitation to deliver drugs or genes to SMCs to 
inhibit smooth muscle proliferation and promote re-endothelialization for vascular 
recovery (Quarck and Holvoet 2004). 
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At higher ultrasound energies, extensive denuding of the endothelium was 
produced at the targeted site, as imaged in Figure 5.2 G-H and quantified in Figure 5.3.  
A targeted loss of viability or denuding may be not be desirable for drug or gene delivery 
applications but may be beneficial for other therapeutic applications.  A number of 
vascular targeting agents, such as combretastatins, are currently being studied to cause 
EC death for anti-vascular targeting (Thorpe 2004).  This therapy aims to selectively 
destroy endothelium of tumor blood vessels and subsequently cause vascular shutdown, 
which limits sustaining nutrients and waste removal required by the tumor (Tozer et al. 
2005).  High ultrasound energies focused at a tumor may be able to create this desired 
effect by denuding the artery. 
In conclusion, this work supported the hypothesis that ultrasound-mediated 
cavitation can target intracellular uptake into ECs.  Furthermore, we have for the first 
time imaged the localized patterns of intracellular uptake and shown them to be 
heterogeneously scattered patches that may correspond to ultrasonic cavitation events.  
These regions of uptake and cell death often appeared to be several cells in diameter, a 
dimension consistent with estimates of  “blast radii” from single cavitation events 
(Guzman et al. 2003; Sundaram et al. 2003) and related observations of denuding cells 
off cultured monolayers (Ohl and Wolfrum 2003).  We have also quantified the 
endothelial bioeffects due to ultrasound-enhanced delivery and found that intracellular 
uptake can occur in up to 24% of ECs at intermediate ultrasound energy and that 
widespread denuding of ECs from the arterial surface can occur at high energy.  Using 
intact arteries as an ex vivo drug delivery model, this study showed that the same 
bioeffects occur at near physiologic conditions.  These results exhibit advantages and 
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limitations of ultrasound-enhanced delivery that can further guide research on this 








 Advances in biotechnology rely on techniques such as electroporation (Gehl 
2003), liposomes (Goyal et al. 2005; Simoes et al. 2005), viral vectors (Young et al. 
2006), microinjection (Jensen et al. 2003), and other emerging technologies to 
intracellularly deliver molecules into the cytoplasm and/or nucleus to modulate cellular 
behavior.  These studies often aim to deliver bioactive molecules, such as genetic 
material or proteins, (Azzam and Domb 2004) or diagnostic molecules in order to label 
organelles or cellular structures (Barber et al. 1996).  Current techniques to permeabilize 
cells for intracellular uptake encompass many different mechanisms to bypass the cell 
membrane, an impediment to molecular transport.  These include electric means as with 
electroporation (Li 2004); chemicals to package molecules for delivery as with liposomes 
(Barber et al. 1996) or cell penetrating proteins (Kerkis et al. 2006); chemical fixation 
followed by permeablizing detergents (Melan 1994); direct injection of material by 
microinjection (Dice 1988); and mechanical means to apply shear stress to open cells as 
with scrape loading (McNeil et al. 1984), shockwaves (Kodama et al. 2002), and 
cavitation (Schlicher et al. 2006).  Even though all of these techniques have developed  
into effective methods, they each have disadvantages such as requiring expensive 
_________________________________ 
2This work was carried out in collaboration with Dr. Pavel Kamaev, whose contribution 
included the study of DU145 cells exposed to the cell shearing injury device (CSID). 
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equipment or chemicals, being complex to perform and time-intensive, being effective 
for only a small number of cells, or only being capable with non-viable cells as with 
chemical fixation and detergent protocols.  Developing a means that is inexpensive, 
simple to perform, and effective at intracellular delivery of molecules into viable cells 
would greatly benefit biological research, biotechnology processes, and possibly the 
clinic. 
 A novel solution, which is being developed in our lab, is cell permeabilization by 
shear forces from fluid flow.  We have found that flow of in vitro cells in suspension 
through microchannels, thereby exposing cells to high shear, can cause intracellular 
uptake of molecules.  The potential advantages of this device are its low cost, ease of use, 
ability to be used for high throughput, and effective intracellular delivery.  
 Shear permeablization of cells is commonly believed to cause increased 
membrane tension and subsequent poration of the cell membrane (Lokhandwalla and 
Sturtevant 2001; Netz and Schick 1996).  The first studies of membrane tension involved 
pore formation by using micropipetting techniques on red blood cells.  These studies 
found that the critical areal strain is 2-3% and the critical tension is approximately 10 
mN/m3 before membrane poration and subsequently cell lysis in red blood cells, which 
lack the ability to repair actively (Evans et al. 1976).  Later developed techniques to 
induce shear forces and tension upon cells include fluid flow in viscometers (Clarke and 
McNeil 1992) or hypodermic needles (Clarke and McNeil 1992), shock waves induced 
by lasers (Doukas and Kollias 2004; Kodama et al. 2002; Mulholland et al. 1999) or 
ultrasound  (Lokhandwalla and Sturtevant 2001), and cavitation activity mediated by 
lasers or ultrasound (Miller et al. 1996; Ohl and Wolfrum 2003; Rau et al. 2004).  
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Furthermore, it is believed that cellular shearing is a critical event in injury (i.e., 
traumatic brain injury) leading to cell death or dysfunction due to cell permeablization 
(Prado et al. 2005).  
 Guided by these findings, we sought to (i) systematically study the effects of 
different shearing environments on cellular uptake and viability, (ii) assess the breadth of 
applications of uptake of different sized molecules, and (iii) design a simple and 
inexpensive device for applications. 
Results 
Shear-induced intracellular uptake 
 Our hypothesis is that controlled flow through microchannels can cause shear-
induced loading of cells with macromolecules.  As a first step toward testing this 
hypothesis, we exposed DU145 prostate cancer cells to controlled shear forces in a cone-
and-plate cell-shearing injury device (CSID) that applied a uniform shear force to a 
monolayer of adherent cells in the presence of calcein (a cell-impermeant, green-
fluorescent molecule), in the CSID.  As shown in Figure 6.1, flow cytometry histograms 
of green fluorescence and display a control sample (i.e., no shear exposure) exhibiting 
innate autofluorescence and background noise, and a sample exposed to shear (i.e., 140 
dynes/cm2 for 300ms) displaying an increase in the number of cells with green 
fluorescence, indicating intracellular uptake of calcein.  This result demonstrates that 
large transient shear forces can induce permeablization and cause intracellular uptake of 
molecules.   
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Figure 6.1:  Flow cytometry histogram of green fluorescence displaying a control 
sample (solid line) and a sample exposed to shear in the CSID (dotted line), which 
exhibits an increase in green fluorescent indicting intracellular uptake of calcein. 
 
Building from these results, we exposed cells in suspension to shear by flow 
through our fabricated microchannel device (Figure 3.2C).  In Figure 6.2, representative 
flow cytometry and fluorescent microscopy results display intracellular uptake into viable 
cells after cells were exposed to fluidic shear in microchannels.  The dashed curve in 
Figure 6.2A displays heterogeneous uptake that was typical at low shear conditions.  The 
dotted curve in Figure 6.2A shows that higher shear caused intracellular uptake of calcein 
into a larger fraction of cells in a more homogenous manner.  In Figure 6.2B, fluorescent 
microscopy displays cells with intracellular calcein and some dead cells, as stained with 
propidium iodide, verifying intracellular delivery of calcein into viable cells. 
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Figure 6.2:  (A) Flow cytometry histogram of green fluorescence displaying a 
control sample and a sample subjected to low and high shear environments, which 
display an increase in green fluorescence indicting intracellular uptake of calcein.  
(B) Fluorescent miscrocopy image of cells after exposure to shear in microchannel 
flow, which depicts viable cells with intracellular uptake green-fluorescent calcein 
and non-viable cells stained with red-fluorescent propidium iodide. 
 
Quantification of shear-induced bioeffects 
Having demonstrated that controlled flow through microchannels can cause 
loading of cells with molecules, we further sought to systematically evaluate the effects 
of shear environment on uptake and loss of viability by flowing DU145 cells in 
suspension through microchannels of various dimensions.  In Figure 6.3, the effects of 
fluid flow rate and microchannel diameter and length were examined.  Fluid flow rate 
was varied up to 100ml/h, which was the maximum our apparatus could accommodate.  
Increased flow rate should increase the intensity of the shear force experience by a cell, 
while decreasing its duration.  Microchannel diameter was varied down to 50 μm, which 
is approximately three times the cell diameter of 15-18 μm.  Smaller diameters were 
found to clog and were therefore no used.  Decreasing microchannel diameter should 
increase the shear intensity without changing its duration. Finally, microchannel length 
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was varied up to 250 μm, which was the maximum our apparatus could accommodate, 
due to the increased pressure drop associated with longer channels.   
Figure 6.3 shows that significant effects on intracellular uptake and cell viability 
occurred under the different shearing conditions.  In each graph, the total height of each 
bar represents the percent of cells remaining intact after shear exposure, which is 
subdivided into a black bar, representing the percent of viable cells with uptake (the 
typically desirable population), a grey bar, representing the percent viable cells without 
uptake (the apparently unaffected population), and a white bar, representing the percent 
of intact dead cells (the population stained with propidium iodide).  All samples were 
normalized to the control sample (i.e., no shear exposure) taken to represent 100% 
viability and 0% uptake.   
Figure 6.3 indicates that decreasing channel diameter and channel length each 
increased the number of cells with intracellular uptake (ANOVA, P < 0.05).  A general 
trend in the viability could not be inferred, since at low shear the 250 μm channels 
display a higher viability and at high shear the 100 μm channels exhibit a higher viability.  
Increasing the flow rate over the range tested did not significantly change the intracellular 
uptake observed (ANOVA, P > 0.05).  Overall, uptake by approximately 10% of cells 
was achieved with minimal viability loss and uptake in excess of 20% of cells was 
achieved with 20-50% viability loss.  These results generally suggest that high shear 
conditions created by small diameter channels and short exposure times are favorable for 
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Figure 6.3:  Cell viability and intracellular uptake populations following shear 
exposure within cylindrical microchannels of various dimensions.  The total height 
of each bar represents the fraction of cells remaining intact, the size of the black 
stripe represents the fraction of cells with significant levels of intracellular uptake, 
the size of the grey stripe represents the fraction of cells that were apparently 
unaffected, and the size of the white bar represents the fraction of cells that were 
intact and dead.  DU145 cells were subjected to shear by passage through 
microchannels of (A) 100 μm and (B) 250 μm channel length.  Data in represent the 
averages of n ≥ 3 replicates with SEM shown. 
 
 
To test the hypothesis that shear stress is responsible for the bioeffects, the 
average shear stress was estimated all of the flow conditions and graphed in Figure 6.4.  
The actual shear stress experienced by the cells is expected to be vary, becuase the 
velocity profile was not fully developed over the short channel lengths and regions of 
higher shear rates will exist near the channel wall and lower shear stress in the center of 
the channel.  In Figure 6.4, uptake was shown to increase and viability was show to 
decrease with increasing average shear force (ANOVA, P <0.0001).  This result suggests 
that shear stress mediated the bioeffects, and that high shear forces are desirable for 
delivery to a larger number of cells.  Differences between 100 μm (Figure 6.4A) and 250 
μm (Figure 6.4B) channel length suggest that high shear for short durations are favorable 










































































































































































































Figure 6.4:  Correlation of cell viability and uptake measurements with average 
shear stress calculated for exposures within (A) 100 μm and (B) 250 μm channel 
lengths.  The total height of each bar represents the fraction of cells remaining 
intact, the size of the black stripe represents the fraction of cells with significant 
levels of intracellular uptake, the size of the grey stripe represents the fraction of 
cells that were apparently unaffected, and the size of the white bar represents the 
fraction of cells that were intact and dead.  Data in represent the averages of n ≥ 3 
replicates with SEM shown. 
 
Intracellular delivery of molecules by shear 
 We next wanted assess the breadth of molecules that could be loaded into cells by 
testing the uptake of different sized macromolecules.  Molecules ranging in size from 0.6 
to 2,000 kDa were incubated with cells and exposed to shear by flow through channels of 
50 μm diameter and 100 μm lengths at a flow rate of 100 ml/h.  As shown in Figure 6.5, 
all five of the molecules tested, including large dextrans and bovine serum albumin 
(BSA) were able to be loaded intracellularly by shear exposure.  These findings show that 
large macromolecules can be delivered transiently shearing cells, which indicates that 
shear-induced disruptions to the plasma membrane barrier ar big enough to permit entry 
of large macromolecules (e.g. 2,000 kDA dextran).  Moreover, this observation suggests 
that shear-induced loading of cells could be developed into a useful tool for intracellular 
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delivery of molecules with biological significance, such as intracellular stains, proteins 
































Figure 6.5:  Intracellular delivery of various molecules by subjecting DU145 cells to 
shear in cylindrical microchannels with dimensions of 50 μm diameter and 100 μm 
channel length.  The total height of each bar represents the fraction of cells 
remaining intact, the size of the black stripe represents the fraction of cells with 
significant levels of intracellular uptake, the size of the grey stripe represents the 
fraction of cells that were apparently unaffected, and the size of the white bar 
represents the fraction of cells that were intact and dead.  Data in represent the 
averages of n ≥ 3 replicates with SEM shown. 
 
Simplified device with conical microchannels 
 To facilitate practical use, we sought to design a simplified device that could be 
attached onto a syringe and allow one to manually expose cells to shear by passage 
through microchannels and thereby cause intracellular loading in the laboratory.   
Microchannels were fabricated in a 3 x 3 configuration, yielding nine channels, for higher 
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throughput and to reduce the incidence of channel clogging.  Also, based on the 
observation that high stress for short durations is favorable, we created conical 
microchannels that maximized the shear stress just at the channel outlet (Figure 3.2B) 
(Martanto et al. 2005).  Conical microchannels were drilled using the excimer laser in a 
trepanning mode to yield an inlet diameter of approximately 300 μm and exit diameter of 
40 and 50 μm over a 250 μm channel length.  To simulate simplified laboratory use, 
these channels were tested by manually dispensing the syringe containing approximately 
3 ml of cell solution instead of using the syringe pump.  As shown in Figure 6.6, this 
approach produced significantly improved results with higher viabilities and a larger 
percent of cells with intracellular uptake such that uptake.  For example, uptake in 36% 
of cells was achieved while maintaining a cell viability of 80%.  We believe this 
increased effectiveness was due to the use of conical channels that achieved a very short 
exposure to high shear stress.  This work also illustrates that a simple, hand-operated 

































Figure 6.6:  Intracellular uptake and viability populations after manually dispensing 
cells through conical microchannels.  Microchannels were fabricated a 3 x 3 array (9 
total channels) with inlet diameter of 300 μm and an outlet diameter of (A) 50 μm 
and (B) 40 μm.  The total height of each bar represents the fraction of cells 
remaining intact, the size of the black stripe represents the fraction of cells with 
significant levels of intracellular uptake, the size of the grey stripe represents the 
fraction of cells that were apparently unaffected, and the size of the white bar 
represents the fraction of cells that were intact and dead.  Data in represent the 
averages of n ≥ 3 replicates with SEM shown. 
 
Discussion 
In this study, intracellular delivery of molecules was evaluated by subjecting cells 
to shear stress by fluid flow in the controlled environment of a cone and plate shearing 
device and in a novel device that exploited the high shear environment of fluid flow 
through microchannels.  Shear stress proved to be a functional mediator of intracellular 
uptake as we demonstrated the uptake of small and macromolecules into a large number 
of cells.  Most importantly, this work led to the development of a simple and inexpensive 
device that can expose a large number of cells to shear, thereby delivering molecules into 
cells. 
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By evaluating the shearing environment in terms of the microchannel dimensions 
and geometry, we have concluded that the most favorable shearing environment for high 
uptake and viability is high magnitude shear for short durations, as illustrated by the 
conical microchannels.  Conical microchannels were created with large inlet diameters 
and small outlet diameter, which were on the order of magnitude of the cell diameter.  It 
is expected that the large inlet diameter (approximately 300 μm) produced insignificant 
shear forces on the cell as was observed in the large cylindrical channels, such as 70-80 
μm diameters channels (more than three times smaller than the conical channel inlet). 
However, as the channels decreased diameter with the conical profile, higher velocities 
were achieved creating a shear environment similar to the small cylindrical channels, 
such as 50 μm diameter channels, yet with much shorter durations.  We believe high 
magnitude shear and short exposure durations were the principle factors that led to higher 
viabilities and more cells with intracellular uptake. 
A device for flowing fluid through the microchannels was created with the 
following design consideration: (i) allow coupling of a syringe and tubing for dispensing 
and collecting, respectively, (ii) provide a water tight seal around the microchannel disks 
to ensure fluid flow through the microchannels, and (iii) allow microchannel disks to be 
easily replaced within the device.  The fabricated device, as shown in Figure 3.2 C, 
proved to be suitable for dispensing and collecting small volumes (3 – 10 ml) of cell 
solution, however, other designs could be imagined for flowing larger volumes of cell 
solution.  A number of the samples tested with single channel disks (Figure 6.1 B) had 
the incidence of high resistance during fluid flow, which we attributed to cells or cellular 
debris accumulating in the channel and obstructing flow.  Using micro-machining 
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techniques, we were able to create Mylar® disks with an array of microchannels (Figure 
3.2 B) that nearly eliminated the incidence of clogging and allowed for higher throughput 
of the cell solution.  The ease of use of this device with an array of conical microchannels 
was demonstrated by manually dispensing cell solution (Figure 6.6) 
  By demonstrating intracellular of small molecules to large macromolecules and 
proteins, this study showed the potential of our device to be useful for intracellular 
delivery of molecules in a number of biological applications.  Intracellular delivery is 
pursued by a number of techniques such as electroporation, liposomes, viral vectors, and 
microinjection to deliver bioactive molecules to alter cellular processes and diagnostic 
molecules into cells to label cellular structures for live cell imaging and analysis.  
Possible areas that could benefit from this device include in vitro studies in biological 
laboratories, ex vivo cell based clinical therapies, biotechnology processes, and 
pharmaceutical laboratories for drug discovery and testing of intracellular targets. 
In conclusion, we have demonstrated the potential of shear forces to cause 
intracellular uptake and have fabricated a novel device that uses shear to deliver 
molecules into a large number of cells.  The advantages of this device are its low-cost, 
ease of use, ability to be used for high throughput systems, and effective intracellular 
delivery of small and large molecules.  However, limitations of this device are its 
hetergeneous effect and loss of viability.  Despite these limitations, we believe this device 
or one of similar design will be a beneficial tool to deliver molecules into cells for the 






The success of the next generation of medicinal treatments will not only require 
the discovery of new therapeutic drugs but will also greatly depend on new and more 
effective methods of drug delivery.  Advancements to conventional drug delivery 
methods are aimed at reducing the inefficiencies of the delivery process, particularly by 
targeting specific cells or tissues and more effectively penetrating the cell membranes, 
which are impediments to drug transport.  Inefficiencies in the delivery process lead to 
poor efficacy of the drug or gene and often require much higher doses, which causes 
higher costs and unwanted side effects.  Ideally one would desire to administer a 
therapeutic agent that would effectively target and deliver to specific cells or tissues at 
high efficiency.  Such a system would provide a great benefit in a broad range of drug 
delivery applications by increasing the efficacy of current drugs, lowering administrating 
costs, decreasing side effects, and promoting future gene therapy and drug design. 
Ultrasound-enhanced delivery is a novel and exciting technique that is being heavily 
researched because it offers the potential to address these issues by targeting intracellular 
delivery in a non- or minimally invasive manner. 
 In this study, we first sought to measure cavitation, which is the mechanism by 
which ultrasound induces intracellular delivery, as a means to monitor the kinetics of 
cavitation activity and predict bioeffects.  During exposure of cell suspensions to 
ultrasound in an in vitro system, we used a passive cavitation detection system that 
allowed recording of sound emissions from cavitation activity.  Recorded sound 
emissions were then processed by FFT analysis to derive the frequency spectrum.  These 
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spectra showed characteristic features of bubble oscillation and collapse, including 
increased magnitudes at harmonics and increased levels of broadband noise.  Generally, 
we found that the broadband noise increased sharply and peaked during the first 20 ms of 
ultrasound exposure and then decayed with a half-life of tens to hundreds of milliseconds 
until reaching a point of constancy.  The sudden rise in broadband noise has been 
generally accepted to coincide with the initial collapse of stabilize microbubbles and the 
collapse of secondary bubbles.  The decay in broadband noise is attributed to the 
destruction of secondary bubbles resulting in a lack of bubbles available for collapse.  
From measuring the peak broadband noise, the time to reach peak broadband noise, and 
the half-life at different frequencies, pressures, and microbubble concentrations, we 
found the kinetics greatly differed over these parameters.  For instance, increasing 
pressure increased the peak broadband noise, whereas increasing frequency decreased the 
peak broadband noise, and increasing microbubble concentration did not consistently 
change the peak broadband noise  In conclusion, we hypothesize that two factors 
principally control the kinetic activity of inertial cavitation in our system and hence the 
measured broadband noise: these are (1) the initial number of bubbles capable of 
undergoing inertial cavitation (i.e., bubbles within the size range for inertial cavitation, 
which depends primarily on acoustic pressure and frequency and Optison concentration) 
and (2) the rate of destruction of bubbles by inertial cavitation, which depends on the 
volume of the sample exposed to a pressure above the pressure threshold for inertial 
cavitation. 
To obtain a measurement of the overall inertial cavitation activity, we used the 
time integral of broadband noise, termed cavitation dose, over the exposure duration.   
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We found that cavitation dose correlated broadly with bioeffects over a range of 
experimental and acoustic parameters, including acoustic pressure, exposure time, 
frequency, and microbubble concentration.  We further showed that measuring the output 
parameter of broadband noise from cavitation emissions offers a means to predict 
bioeffects that is superior to the measurement of input parameters such as acoustic 
energy, which can not always predict the cavitation activity.  Overall, these results 
demonstrate that passive cavitation detection and measurement of broadband noise is a 
unifying parameter that could be used as a feed-back measurement in the lab and 
potentially in the clinic to non-invasively measure cavitation and predict bioeffects.  
In this study, we also investigated the use of ultrasound to cause targeted 
intracellular delivery into tissue, advancing this technique beyond previous experiments 
with in vitro cell suspensions.  For these studies, we chose to focus on arterial tissue 
because it presents a favorable location for cavitation production (i.e., the blood stream) 
and a number of cardiovascular diseases could benefit from targeted drug delivery.  We 
found that by exposing viable ex vivo porcine carotid arteries to ultrasound in the 
presence of microbubbles and a model drug, we could cause targeted intracellular 
delivery to endothelial and smooth muscle cells.  Using confocal microscopy to image 
and then quantify the bioeffects, we found that at low to intermediate ultrasound energy, 
ultrasound can achieve targeted intracellular delivery into viable cells in 9 – 24% of 
exposed endothelial cells.  These conditions also typically caused 7 - 25% endothelial cell 
death.  Approximate ultrasound energy for in vivo applications can be deduced from these 
quantitative results.  At high energy, intracellular delivery was targeted to smooth muscle 
cells, which was associated with denuding or death of proximal endothelial cells.  
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Furthermore, it was determined that the internal elastic lamina poses the main barrier to 
cavitation effects on medial cells and that high ultrasound energies are necessary for 
delivery to smooth muscle cells.  From images of the artery after ultrasound exposure, the 
distribution of cells with uptake and death appeared as heterogeneously scattered patches, 
which are hypothesized to correspond to ultrasonic cavitation events.  Lastly, we used 
intact arteries in a custom-designed chamber that allowed us to approximate physiologic 
conditions of pressure, tension, and fluid properties (i.e., by using whole blood).  In these 
experiments, we found that bioeffects appeared similar to those measured in quantified 
experiments.  In conclusion, this work supported the hypothesis that ultrasound-mediated 
cavitation can target intracellular uptake into endothelial cells.  Furthermore, we have for 
the first time imaged the localized patterns of intracellular uptake and shown them to be 
heterogeneously scattered patches that may correspond to ultrasonic cavitation events.  
Using intact arteries as an ex vivo drug delivery model, this study showed that the same 
bioeffects occur at near physiologic conditions. These results exhibit ultrasound’s 
advantages for causing targeted intracellular uptake into endothelial cells and smooth 
muscle cells and also the limitations due to heterogeneous uptake and loss of viability in 
the form of denuding and cell death.  The understanding gained from these results can 
further guide research on this technique for drug or gene delivery applications to treat 
cardiovascular diseases and dysfunctions. 
 Lastly, in this study, we evaluated high shear stress exposure to cells in order to 
induce intracellular uptake.  Shear stress from cavitation oscillations and collapse is 
commonly believed to be the primary mediator of intracellular uptake by ultrasound as 
well as in a number of other techniques such as shockwave exposure.  Building from 
 98
these findings, we explored the use fluid flow through microfluidic channels to impart 
high shear forces for short durations on cells.  Using this technique, we found that we 
could achieve intracellular uptake of small and large macromolecules into cells.  We 
believe this phenomenon closely mimics the shearing mechanism by which ultrasound-
mediated cavitation causes bioeffects.  However, at optimal shearing conditions, 
intracellular uptake could be achieved in a large portion of the exposed cells in a more 
homogenous manner than with ultrasound exposure.  We believe these optimal conditions 
exposed cells to a more homogeneous shear stress than the shear stress generated from 
localized cavitation bubbles during ultrasound exposure.  In conclusion, we believe this 
method offers a simple, quick, inexpensive, and high-throughput method for delivering 
molecules into cells.  We believe this method could be further developed for applications 
to intracellularly deliver bioactive molecules (e.g., genetic material or drugs) or 
diagnostic labeling probes in an in vitro laboratory setting or possibly for ex vivo clinical 
purposes. 
 Overall, this thesis presents data that advances ultrasound-enhanced drug delivery 
on two major fronts: (i) the challenge in controlling cavitation-mediated bioeffects in 
vitro were addressed based on cavitation detection and correlation of bioeffects with the 
unifying broadband noise measurement and (ii) the advancement of this method toward 
an in vivo application was furthered by the evaluation of this method to deliver molecules 
into cells in viable ex vivo tissue.  From these findings, it is expected that the cavitation- 
mediated bioeffects could be controlled in an in vivo application by a feedback-
measurement based on cavitation detection.  Furthermore, the proper acoustic energies 
and treatment strategies (e.g., repeated exposures) for in vivo can be inferred from our 
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results with ex vivo arteries.  Lastly, this thesis has presented a novel method for 
intracellular delivery by exposing cells to shear forces in fluid flow through 
microchannels.  Delivery of small to large molecules was demonstrated and the near 
optimal shear environment was determined.  It is expected that this method could be 
further developed to aid biological research or cell based therapies by delivery of 







For future studies of ultrasound-enhanced drug delivery, I would recommend 
continuing to focus on drug and gene delivery to vascular tissue for treatment of 
cardiovascular diseases and dysfunctions.  I believe the most probable scenario for 
ultrasound as a successful drug or gene delivery modality is employing ultrasound for 
targeted treatment to the cardiovascular system.  Foremost, there is a need for a targeted 
drug delivery in the cardiovascular system for treatment of specific diseased sites such as 
atherosclerotic lesions (e.g. vulnerable plaques), restenosis post percutaneous 
interventions, and regions of ischemic tissues.  Furthermore, I believe the cardiovascular 
system is an area in the body that is most conducive for ultrasonic delivery because 
cavitation can be readily produced in the blood, and drugs and microbubbles can easily 
access most of the cardiovascular system via intravenous injections and transport by 
blood flow.  To advance ultrasound-enhanced drug delivery toward a clinical treatment, I 
would recommend concentrating on (1) delivery in ex vivo systems for optimization of 
delivery of various molecules and genetic material, (2) delivery in in vivo systems to 
determine the performance of this technique in vivo, (3) the inflammation and injury 
caused by this technique, and (4) employing this techniques for treating disease models in 
in vivo systems. 
Building from the intact artery experiments in this thesis, I believe further ex vivo 
experiments in a system comprised of viable excised arteries maintained in an organ 
culture system offers an excellent way to study the ability of ultrasound for drug and gene 
delivery.  Using this system, intracellular delivery of various molecules from small 
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molecules (as shown in this thesis) to macromolecules (e.g., proteins) into endothelial 
and smooth muscle cells can be studied.  In addition, there has been an increase research 
on ultrasound for gene therapy, however, most have used in vivo systems and have not 
fully quantified the percent of cells with gene expression.  An ex vivo system as described 
would offer an approach to quantify and image gene expression of reporter plasmids to 
fully determine the capabilities of this technique.  Furthermore, many of these studies 
have not fully investigated the cavitation activity occurring during treatment and many 
have not characterized the ultrasound exposure (e.g. in terms of peak pressure, area of 
exposure, and exposure time).  Many of these experiments have also employed DNA-
loaded microbubbles, and it is not fully understood if this increases gene expression.  I 
believe there is an area of need to understand the cavitation activity in terms of the type 
of cavitation (i.e., stable or inertial) and the level of cavitation that is inducing gene 
expression.  Experiments could employ a cavitation detection system as used in this 
thesis to determine the type and level of cavitation.  These studies could shed insight on 
the mechanism of cavitation-induced gene expression. 
Future studies should also evaluate this technique in an in vivo setting for drug 
and gene delivery.  Even though the ex vivo system provides an excellent system for 
study, it can not mimic the injury and healing response that would be experienced in vivo.  
Therefore, I would recommend experiments in animal models to evaluate the bioeffects 
of intracellular uptake or gene expression and the viability post ultrasound treatment.  A 
possible limitation of this technique may be the injury and inflammation response from 
the physical effects of cavitation.  Vascular injury by mechanical means such as 
angioplasty or stenting typically causes an inflammatory response in the form of platelet 
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adhesion, leukocyte recruitment, cellular responses such as endothelial apoptosis and 
smooth muscle cell proliferation, and release of proinflammatory and prothrombogenic 
cytokines.  Such a response would be greatly undesired during treatment of the 
cardiovascular system, especially in the case of treating atherosclerotic plaques where 
inflammation could worsen the condition or cause thrombosis.  The use of cavitation in 
the cardiovascular system, by combining microbubbles contrast agent and diagnostic 
ultrasound, has been deemed safe and used for many years.  However, diagnostic 
ultrasound typically uses low energy - low pressure ultrasound that only mediates stable 
cavitation, whereas, intracellular delivery is commonly believed to require the more 
intense inertial cavitation.  Inertial cavitation at high ultrasound energies has been found 
to cause some vascular injury by causing capillary rupture (Hwang et al. 2005), 
endothelial cell death, and denudation in ex vivo tissue, as shown in this thesis.  It is 
critical to understand the injury and inflammatory reaction by ultrasound mediated 
cavitation to determine the safety and limitations of this technique before application in a 
clinical situation. 
 Based on the results of the recommend experiments and identifying intracellular 
targets or therapeutic genes, I believe treatment of diseases will be feasible and should be 
attempted in animal models. Understanding the capabilities for intracellular delivery, 
finding the optimal ultrasound conditions for proper cavitation activity, and knowing the 
limitations in terms injury and inflammation should allow for treatment strategies to 










 As described in Chapter 3 Methods, ultrasound was applied to a sample in a 
custom-built water bath.  Figure A.1 displays a schematic of the equipment used to 
expose samples to ultrasound and record cavitation emissions.  Samples were accurately 
placed within the bath by using a micropositioning system (Velmex). Ultrasound was 
produced at 1.1 and 3.1 MHz by a submersible piezoceramic transducer.  An acoustic 
absorber was place at the opposing end of the tank to minimize acoustic reflections and 
standing wave formation.  The response of the transducer was controlled by driving 
electronics that included: two function generators (Standford research instruments and 
Agilent), a RF amplifier (Electronic Navigation Industries), and a matching network.  To 
record cavitation emissions, a focused hydrophone (Sonic Concepts) was placed 
perpendicular to ultrasound beam.  The signal from the focused transducer was sent 
through a preamplifier before being recorded by a high-speed digitizer (National 
Instruments) in a local computer.  The first function generator acted as the “switch” to 
turn the ultrasound “on” and “off” by creating a square wave where the ultrasound was 
turned “on” at a high voltage and “off” at a low voltage of the square wave.  The square 
wave produced by the first function generator could be customized for the desired 
ultrasound “on” and “off” time (or duty cycle) as well as the number of bursts.  The 
signal from the first function generator was sent to the computer to initialize recording of 
the ultrasound burst and to the second function generator as an external trigger to control 
the burst of ultrasound.  The parameters of ultrasound (i.e., frequency and pressure) were 
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controlled by the second function generator by inputting the desired frequency and 




Figure A.1:  Equipment schematic of the ultrasound bath and electronics. 
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 Mapping and calibration of the acoustic field produced by the ultrasound 
transducer was performed to determine the optimal location for sample placement and to 
calibrate the function generator voltage input to the ultrasound pressure output at the 
desired sample location. 
 
METHODS 
 Mapping and calibration of the piezoceramic transducer was carried out as 
described in Chapter 3 Methods. 
 
RESULTS 
Mapping of the acoustic field 
To determine the optimal sample location axially along the acoustic beam, the 
membrane hydrophone was used to find the focus and then moved axially to measure the 
pressure, as shown in Figure B.1A and B for 1.1 and 3.1 MHz, respectively.  As shown in 
Figure B.1, the focus of each frequency was the location with the highest pressure 
measured, approximately at 5.1 - 5.4 cm from the transducer face for both frequencies.  
For both frequencies, there were also local maxima were the pressure peaked just before 
and after the focus.  These local maxima are due to the constructive and destructive 
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Figure B.1:  Mapping of temporal-peak-negative presssure along the axis of the 
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3.5 cm 4.5 cm 5.0 cm 5.5 cm  
Figure B.2:  Mapping of the temporal-peak-negative pressure transversely along the 






To measure the transverse width along the ultrasound beam, the hydrophone was moved 
perpendicular to the beam.  In Figure B.2A and B, the transverse mapping of the acoustic 
beam is shown for 1.1 and 3.1 MHz, respectively.  As shown in Figure B.2, the beam 
width decreases as hydrophone approaches the focus and increases passed the focus.  To 
display the acoustic profile graphically, Figure B.3A and B displays the data of the 
transverse data along the axial distance from the transducer for 1.1 and 3.1 MHz, 
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3.6 cm 4.5 cm 5.0 cm 5.5 cm  
Figure B.3:  Focused ultrasound beam profile of ultrasound emitted at (A) 1.1 and 
3.1 MHz. 
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Based on these results, the sample location was chosen to be placed at the local 
maximum immediately prior to the focus.  This location was chosen because of the wider 
beam width, approximately 10.4 mm and 2.4 mm wide at half-amplitude (-6 dB) for 1.1 
and 3.1 MHz, respectively. A wider beam width allowed more of the sample to be 
exposed to ultrasound and the local maximum still allowed high pressures to be produced 
at this location. 
 To calibrate the input voltage to the output ultrasound pressure, the hydrophone 
was used find the focus and then moved towards the transducer to find the local 
maximum, the desired sample location.  At this location, the voltage was varied from 
approximately 0.1 mVpp to 4.0 mVpp while measuring the pressure with the 
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Figure B.4:  Calibration of temporal-spatial-peak negative pressure with the 
function generator voltage at the local maximum prior to the focus. 
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 LabVIEW and MATLAB programs were written to aid in recording and 
analyzing cavitation emissions, respectively.  The LabVIEW program was written 
specifically to control the high-speed digitizer, which was installed in a personal 
computer and recorded the emissions in a digital format.  A MATLAB program was then 
written to take the digital files of recorded cavitation emissions and apply Fast-Fourier 




As described, in the Chapter 3 Methods the cavitation emissions were detected by 
a focused hydrophone that then sent the signal through a pre-amplifier before being 
recorded by a high-speed digitizer, which was controlled by a LabVIEW program.  To 
prepare for a given experiment, a folder on the personal computer was created and named 
the proper date of the experiment.  In the experiment folder, three other folders were 
created and named “Bursts”, “Pictures”, and “Spectrum Data”.  These folders were 
created to keep data organized as it was recorded and processed. An excel file was then 
created in the Spectrum Data folder and named “Conditions.xls”.  This file contained all 
the information needed by the high-speed digitizer to record the cavitation emission, 
including number of samples to be recorded for each burst, the number of bursts, the 
sampling rate, and the voltage range of the emissions.   The voltage range was 
determined before an experiment in a pilot study by measuring output voltage from the 
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pre-amplifier during an ultrasound exposure to a sample containing Optison at the desired 
pressure, location and concentration, respectively. The Conditions file was saved as a text 
file in order to be read by the LabVIEW program.  The LabVIEW program named “Long 
Acquistion-smb.vi” was opened.  Figure C.1 displays the program’s panel interface.  
Prior to recording, the electronics were connected in the correct configuration, the sample 
was placed in the desired location of the ultrasound apparatus, and the driving electronics 
settings were adjusted for the sample.  To begin the exposure, the sample number was 
inputted into the LabVIEW program and the “Run” button was clicked with the mouse to 
start the program.  At this point the LabVIEW program was running and waiting for a 
signal input that would trigger the recording.  Immediately after starting the LabVIEW 
program, the ultrasound was applied by pressing the TRIG button the function generator.  
The output of the LabVIEW program for each sample were files named “sample #.dsc”, 
“sample #.txt”, and “sample #.I16”.  The “.dsc” file was a description file that could be 
opened in Notepad and listed parameters used by the LabVIEW program during the 
recording of each burst, including numbers of samples, sampling period, offset, gain, and 
timer.  The “.txt” file contained information regarding the experimental parameters and 
the data and time of each sample recording.  Lastly, the “.I16” file was a binary data file 
that contains recorded emission for each burst during ultrasound exposoure to a sample. 
Using the gain and offset in the “.dsc” file, the binary data could be converted into actual 
voltage data.   
MATLAB programming 
 The MATLAB program “SpectraBNCorrelation” was used to analyze each 
experiments recording by reading the binary data, converting it to real voltage data, 
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applying FFT, analyzing regions of the frequency spectrum, writing the spectrum data to 
excel files, and graphing spectrum data.  The inputs to the program were the date of the 




Figure C.1: Front panel of Labview program to control the high-speed digitizer for 













Figure C.4:  Diagram view of Labview program: Read Conditions-smb.vi 
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%read conditions for experimental parameters 
conditions=xlsread(['B:\Experiments\',Date,'\Spectrum Data\Conditions.xls']);  %read conditions file 

















if strcmp(sample_end,'Max')==1   
    sample_end=max(c_samples); 
end 
['Samples to be analyzed: ',num2str(sample_start), ' through ', num2str(sample_end)] 
 
for k=[sample_start:sample_end]    %index for samples analyzed    
    File=['sample ',num2str(k)] 
     
    if strcmp(First_Burst_Only,'Yes')==1 
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        Bursts =1 
    else 
        Bursts = c_bursts(k);        %Number of bursts to be analyzed 
    end 
     
    if Bursts >0;   %establishes if sample is a control and skips-controls should have 0 bursts in the 
conditions file  
         
        ['Reading sample ',num2str(k),' i16 Binary File.....'] 
        fid1=fopen([Data_dir,File,'.i16'],'r','b'); %Open specific i16 binary file which contains the signal  
        if fid1 ~= -1                               %establishes if file exists then proceeds-skips controls or samples not 
recorded, which have no files     
             
            fid2=fopen([Desc_dir,File,'.dsc']);     %Open specific description file which contains the sampling 
frequency, signal gain and offset 
            ds=fscanf(fid2,'%g',[5,inf])';          %creates a matrix 'ds' that contains the information from the 
description file 
            fclose(fid2); 
             
            ['Analyzing sample ',num2str(k),' - ',num2str(Bursts),' bursts.....'] 
            for j=1:Bursts    %index for burst of specified file 
                
                 
                fseek(fid1, 2*(j-1)*c_actualspb(k), 'bof'); %seeks within the binary file to start the fread at the 
correct burst 
                y = fread(fid1,c_actualspb(k),'int16');  %reads the binary file 
                 
                %Read from the desciption matrix 'ds' for specific parameters for each burst 
                Period=ds(j,2);  %Sampling Period 
                fs=1/Period;     %Sampling Frequency 
                fn=fs/2;         %Nyquist Frequency 
                Gain=ds(j,4);    %Gain for binary data     
                Offset=ds(j,3);  %Offset for binary data 
                 
                %Apply offset and gain to convert 'y' from binary data to real voltage data 
                %Create relative time matrix for plotting 
                y=y*Gain+Offset; 
                t=0:Period:(length(y)-1)*Period; 
                %                
                if strcmp(Hanning_Window,'Yes')==1 
                    w=hann(length(y)); 
                    y=y.*w; 
                end 
                 
                 
                 
                %Cut acquisiton appropriately for 1 ms signal 
                i=1; 
                while y(i)<0.005 
                    i=i+1; 
                    if i>length(y), break, end 
                end 
                 
                a1=i; 
                a2=a1+12499; 
                if a2 > 13500 
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                    a2=13500; 
                    a1=a2-12499; 
                end 
                y3=y(a1:a2); 
                t3=0:Period:(length(y3)-1)*Period; 
                 
                 
                %Apply FFT, computing magnitude and phase 
                 
                NFFT=2.^(ceil(log(length(y3))/log(2)));   %Next highest power of 2 greater than or equal to 
length of y2 
                FFTY=fft(y3,NFFT);                        %Take fft, padding with zeros, length(FFTY)==NFFT 
                NumUniquePts = ceil((NFFT+1)/2);          %Non-redundant points before Nyquist frequency 
                FFTY=FFTY(1:NumUniquePts);                %Keeping only non-redudant values 
                MY=abs(FFTY);                             %Magnitude  
                MY=MY*2;                                  %Multiply by 2 to take into account the fact that we  
                %threw out second half of FFTX above 
                MY(1)=MY(1)/2;                            %Account for endpoint uniqueness 
                MY(length(MY))=MY(length(MY))/2;           
                MY=MY/length(y3);                         %We know NFFT is even. Scale the FFT so that it is not a 
function of the length of y2. 
                MYD=10*log10(MY);                         %Magnitude in decibels                  
                 
                F=(0:NumUniquePts-1)*2*fn/NFFT;           %Frequency for fft 
                F2=F/DF;                               %Frequency/Driving Frequency 
                R=2*fn/NFFT ;                             %Frequency Resolution 
                 
               
                %Analyzing markers of cavitation 
                %Half Frequency 
                I=round(.5*DF/R); 
                a=I-5; 
                b=I+5; 
                MYDs=MYD(a:b); 
                MYs=MY(a:b); 
                Fs=F(a:b); 
                [C,I]=max(MYs); 
                max_h=MYs(I); 
                frequency_h=Fs(I)/1e6; 
                 
                %Main Frequency 
                I=round(DF/R); 
                a=I-5; 
                b=I+5; 
                MYDs=MYD(a:b); 
                MYs=MY(a:b); 
                Fs=F(a:b); 
                [C,I]=max(MYs); 
                max_m=MYs(I); 
                frequency_m=Fs(I)/1e6; 
                 
                %One and one half Frequency 
                I=round(1.5*DF/R); 
                a=I-5; 
                b=I+5; 
                MYDs=MYD(a:b); 
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                MYs=MY(a:b); 
                Fs=F(a:b); 
                [C,I]=max(MYs); 
                max_oh=MYs(I); 
                frequency_oh=Fs(I)/1e6; 
                 
                %Twice the Frequency 
                I=round(2*DF/R); 
                a=I-5; 
                b=I+5; 
                MYDs=MYD(a:b); 
                MYs=MY(a:b); 
                Fs=F(a:b); 
                [C,I]=max(MYs); 
                max_t=MYs(I); 
                frequency_t=Fs(I)/1e6; 
                 
                % Broad band 1 
                %                 a=round(1.9e6/R); 
                %                 b=round(2.1e6/R); 
                % Broad band 2 
                c=round(2.3e6/R); 
                d=round(2.5e6/R); 
                 
                %                 MYs1=MY(a:b); 
                MYs2=MY(c:d); 
                %                 ave=(sum(MYs1)+sum(MYs2))/(length(MYs1)+length(MYs2)); 
                ave=(sum(MYs2)/length(MYs2)); 
                ave2=10*log10(ave); 
                                
                %Maximum of Magnitude with in these specified ranges (a and b above) 
                Max(j,k,1)=max_h;  %f/2 
                Max(j,k,2)=max_m;  %f 
                Max(j,k,3)=max_oh; %3/2f 
                Max(j,k,4)=max_t; %2f 
                Ave(j,k)=ave;     %broadband noise 
                 
                if strcmp(Make_Plots,'Yes')==1                
                    %Plots 
                     
                    figure(1); 
                    clf; 
                    plot(t3,y3); 
                    xlabel('Time (s)'); 
                    ylabel('Voltage (V)'), grid on; 
                    ylim([-1 1]); 
                    xlim([0 .0015]); 
                     
                    if strcmp(Print_Plots,'Yes')==1    
                        print('-djpeg','-f1','-r200',[Graph_dir,'Waveform-',File,' Burst ',num2str(j),'.jpg']); 
                    end    
                     
                    %Magnitude in decibels Plot 
                    figure (2); 
                    clf; 
                    plot(F,MYD); 
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                    xlim([0 fn]); 
                    ylim([-70 0]); 
                    ylabel('Magnitude [Decibels]'), grid on; 
                    xlabel('Frequency [Hertz]');  
                    title(['Burst ',num2str(j)]); 
                     
                    if strcmp(Print_Plots,'Yes')==1    
                        print('-djpeg','-f1','-r300',[Graph_dir,'FFT-',File,' Burst ',num2str(j),'.jpg']); 
                    end 
                     
                    figure (3); 
                    clf; 
                    plot(F2,MYD); 
                    xlim([0 fn/DF]); grid on; 
                    ylim([-70 0]); 
                    ylabel('Magnitude [Decibels]'), grid on; 
                    xlabel('Frequency/Driving Frequency [-]');  
                     
                    if strcmp(Print_Plots,'Yes')==1    
                        print('-dbmp','-f1','-r300',[Graph_dir,'FFT-',File,' Burst ',num2str(j),'.jpg']); 
                    end                 
                     
                    figure (4); 
                    clf; 
                    plot(F,MY); 
                    xlim([0 fn]); 
                    ylim([0 1.25*max(MY)]); 
                    ylabel('Magnitude'), grid on; 
                    xlabel('Frequency [Hertz]');  
                     
                    if strcmp(Print_Plots,'Yes')==1    
                        print('-djpeg','-f1','-r200',[Graph_dir,'FFT-',File,' Burst ',num2str(j),'.jpg']); 
                    end                  
                     
                    %                     figure (5); 
                    %                     clf; 
                    %                     specgram(y3,NFFT,fs) 
                    %                     title('Spectrogram') 
                     
                elseif strcmp(Make_Plots,'No')==1 
                else 
                    'Make Plots Error' 
                    break 
                end 
                 
            end 
        end  
        fclose(fid1);      




    M(i,1)=c_pressures(i); 
    M(i,2)=Max(1,i,1); %Max value: (Burst, Sample File, four local maximum regions) %f/2 
    M(i,3)=Max(1,i,2); %f 
    M(i,4)=Max(1,i,3); %3/2f 
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    M(i,5)=Max(1,i,4); %2f 
    M(i,6)=Ave(1,i);   %Broad Band measurement(Burst, Sample File) 
     
end 
fid = fopen([Spec_dir,'Maximums Burst 1.xls'],'w'); 





     
    if c_bursts(k)~=0 
         
        for j=1:c_bursts(k) 
             
            B_h(j,k)=Max(j,k,1); %(k=Sample, j=Burst, Region) 
            B_m(j,k)=Max(j,k,2); 
            B_oh(j,k)=Max(j,k,3); 
            B_t(j,k)=Max(j,k,4); 
            BN(j,k)=Ave(j,k); 
        end 
    end 
     
    if c_bursts(k)==0 
        for j=1:1 
             
            B_h(j,k)=Max(j,k,1); %(k=Sample, j=Burst, Region) 
            B_m(j,k)=Max(j,k,2); 
            B_oh(j,k)=Max(j,k,3); 
            B_t(j,k)=Max(j,k,4); 
            BN(j,k)=Ave(j,k); 
        end 
    end 
     
     
    SumBN(1,k)=c_samples(k); 
    SumBN(2,k)=c_pressures(k); 
    SumBN(3,k)=c_bursts(k); 
    SumBN(4,k)=c_energies(k); 
     
    R=[0 0 6.00892E-06 0.000037581 0 4.59264E-06 9.88026E-06
 3.0802E-06 0 0 3.77178E-06 0 7.33868E-06 0.000006496
 0 1.04148E-05 0 1.65894E-05 0 0 
    ]; 
     
     
    if c_pressures(k)==0  
        R1=3.15e-6; 
    elseif c_pressures(k)==0.5  
        R1=3.51e-6 ; 
    elseif c_pressures(k)==1.2  
        R1=3.71e-6; 
    elseif c_pressures(k)==1.7  
        R1=3.62e-6; 
    elseif c_pressures(k)==2.0  
        R1=3.89e-6; 
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    end 
     
    R2=R(k); 
     
    SumBN(5,k)=0;  
    if c_pressures(k)==0  
        SumBN(5,k)=0; 
        u(k)=c_bursts(k); 
         
    elseif c_bursts(k) <=30 
        i=1;  
        u(k)=i; 
        while BN(i,k)>R1 
            SumBN(5,k)=SumBN(5,k)+BN(i,k); 
            u(k)=i; 
            i=i+1; 
            if i>c_bursts(k) 
                break 
            end  
        end 
        SumBN(5,k)=SumBN(5,k)-(u(k)*R1);  
         
    else   
        i=31; 
        SumBN(5,k)=sum(BN(1:30,k)); 
        u(k)=30; 
        while BN(i,k)>R2 
            SumBN(5,k)=SumBN(5,k)+BN(i,k); 
            u(k)=i; 
            i=i+1; 
            if i>c_bursts(k) 
                break 
            end                
        end 
        SumBN(5,k)=SumBN(5,k)-(u(k)*R2);     
    end 
    SumBN(6,k)=u(k); 
      
end 
 
if strcmp(Write_Files,'Yes')==1    
     
    q='%12.8f\n'; 
    for i=1:(max_samples-1) 
        q=['%12.8f\t ',q]; 
    end 
     
    ['Writing files to ',Spec_dir,'....'] 
    fid = fopen([Spec_dir,'Burst_h.xls'],'w'); 
    fprintf(fid,q,B_h'); 
    fclose(fid); 
     
    fid = fopen([Spec_dir,'Burst_m.xls'],'w'); 
    fprintf(fid,q,B_m'); 
    fclose(fid); 
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    fid = fopen([Spec_dir,'Burst_oh.xls'],'w'); 
    fprintf(fid,q,B_oh'); 
    fclose(fid); 
     
    fid = fopen([Spec_dir,'Burst_t.xls'],'w'); 
    fprintf(fid,q,B_t'); 
    fclose(fid); 
     
    fid = fopen([Spec_dir,'Burst_BN.xls'],'w'); 
    fprintf(fid,q,BN'); 
    fclose(fid);    
     
    fid = fopen([Spec_dir,'Sum_BN.xls'],'w'); 
    fprintf(fid,q,SumBN'); 
    fclose(fid);  
     
elseif strcmp(Write_Files,'No')==1  
else 
    'Write Files Error' 













 A sample chamber was constructed to hold an intact artery in place during 
ultrasound exposure.  The design considerations for this chamber were (i) to allow 
ultrasound to pass through the chamber and artery with minimal attenuation from the 
chamber, (ii) to hold the intact artery in place in a horizontal orientation, (iii) to allow 
media to be filled inside the artery to approximately physiologic pressure, (iv) to allow 
media to be filled inside the chamber, and (v) to allow the chamber to be attached to the 
micropositioning system for placement in the ultrasound bath.  In Figure D.1A and B, a 
dimensional drawing and actual image of the intact artery sample chamber is shown, 
respectively.  The chamber was constructed from acrylic plastic for the frame and walls 
of the chamber, Mylar plastic for the ultrasound windows, stainless steel cannulas, and 
polycarbonate compression fittings.  The chamber was constructed such that the acrylic 
walls provided a strong frame and Mylar plastic windows could be attached with screws, 
providing an acoustically transparent window.  A gasket would between the Mylar and 
acrylic was used to provide a water tight seal.  An intact artery could be attached to metal 
cannulas by suturing thread, and cannulas were held in place by compression fittings on 
each of the acrylic frame, which also provide a water tight seal.  Arteries could be filled 
with media through the metal cannulas media.  A simple stopper was used to plug one 
end of the cannulas and some rubber tubing and three-way stop cock was used to allow 
fitting of pressure guage and provide seal.  The chamber, itself, was filled via syringe and 
needle through a small hole in the top of the chamber, which was seal with a rubber 
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stopper.  Lastly, the top of the chamber had a hole bored for a positioning rod and a set 








Figure D.1:  (A) Mechanical drawing of intact artery chamber.  (B) Real image of 









A conical transducer housing was designed and constructed in order to have a 
portable means to produce ultrasound outside of the water bath (e.g., exposure to animal 
models or ex vivo tissue samples).  The design considerations were (i) to have a housing 
that would hold the transducer, (ii) provide a water tight seal, (iii) allow the housing to be 
filled with water, and (iv) allow mounting a micropositioning system.  In Figure E.1, a 
dimensional drawing of the conical housing is shown.  The housing was constructed such 
that the transducer would fit inside the back of the cylindrical portion of the housing with 
a water tight seal.  At the other end, a plastic window could be mounted, also with a 
water tight seal.  This window was typically thin mylar plastic to provide an acoustically 
transparent window.  Near the top of the cylindrical section of the housing a small hole 
was bored for filling the housing with water and could be plugged with a simple rubber  
stopper. The angle of the conical portion was approximately equal to the ultrasound beam 
and was important to allow the ultrasound to be more easily targeted.  The housing could 
allow be mounted to a microposition system via tapped holes on the transducer cover.  To 
further couple the cone to a sample an ultrasonic gel could be used to provide a medium 


























Figure E.1:  Mechanical drawing for conical transducer housing.
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 The use of cavitation in the body is being explored for many uses including 
diagnostic imaging, drug delivery, heating tissues and destroying cells and tissue.  Inertial 
cavitation is of particular interest for drug delivery applications and is currently studied 
for uses in drug delivery to organs and tissues, including kidneys, myocardium, vascular 
tissue, brain, skeletal muscle, spinal cord, and many cancerous tumors.  In each of these 
scenarios, cavitation production is desired to be produced in interstitial spaces or in the 
blood presenting locations were cavitation may be limited due to effects such as 
viscosity.  To study the extent to which viscosity limits inertial cavitation activity, we 
used our established cavitation detection system to measure cavitation is solutions of 
varying viscosities.   
 
METHODS 
High viscosity solutions 
Solutions of glycerin (Sigma, St. Louis, MO) and deionized-distilled water were 
mixed in concentrations ranging from 0 to 85 wt% of glycerin to create twelve solutions 
with viscosities ranging from 0.9 cP (pure water) to 85.5 cP (85 wt% glycerin).  
Viscosities were determined by measuring each solution using a u-tube viscometer 
(Cannon Instrument Company, State College, PA).  In Figure F.1 viscosity measurements 




Ultrasound apparatus and cavitation Detection 
The ultrasound apparatus and cavitation detection system was used as described 
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Figure F.1:  Literature and measured values of the calibration of viscosity with 
concentration of glycerine in a water-glycerine mixture. 
 
Experimental Protocol 
Similar to the protocol in the methods described in Chapter 3, samples were 
prepared by adding Optison® at a concentration of 1.7% v/v (~ 1.1 x 107 bubble/ml) to 
0.5 ml of each glycerin-water solution immediately before ultrasound exposure. 
Ultrasound was exposed at 1.1 MHz to each glycerin-water solution with Optison® at 0.5, 
1.0, 1.5, and 2.0 MPa for 3000 ms of exposure time at a 1% duty cycle while 







 Using our established cavitation detection system and method of analyzing 
inertial cavitation based on broadband noise, we recorded cavitation emissions and 
analyzed the broadband noise signal over the exposure time for each ultrasound exposure.  
In Figure F.2, broadband noise measurements are shown for each solution over a 3000 ms 
exposure of ultrasound at 0.5, 1.0, 1.5, 2.0 MPa.  The higher viscosity solutions display a 
reduction in cavitation activity as indicated by the lower levels of broadband noise, which 
is most distinctive at ultrasound exposure of 2.0 MPa (Figure F.2D).  Lower viscosities 
display a higher in the peak broadband noise and sustained higher levels of broadband 




Figure F.2:  Broadband noise measurements of recorded cavitation emissions 
produced in glycerine-water solutions of various viscosities mediated by ultrasound 




 To further analyze the results presented in Figure F.2, the broadband noise was 
integrated over the exposure time to calculate the inertial cavitation dose, a measure of 
inertial cavitation activity over the exposure time.  As shown in Figure F.3, the inertial 
cavitation dose increases with increasing pressure as expected from previous results.  
With respect to viscosity, the inertial cavitation dose decreased significantly with 
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increasing viscosity.  This data suggests that biological fluids such as blood, which has a 
viscosity of 3-4 cP, will reduce the cavitation activity compared to water (1 cP).  This 
effect of viscosity appears to be more significant at the lower pressures, since the high 
pressures sustained a high inertial cavitation dose whereas the lower pressures diminished 




























Figure F.3:  Measured inertial cavitation dose at various viscosities and peak-
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